Early vs delayed PVI for claudication: known-truth simulation, draft results

Draft scale: n = 50,000 patients, 100 replicates per world x scenario

Read this first

• Run. 8 worlds × 3 truth scenarios × 100 replicates of 50,000 patients (about 1,500 physicians per replicate). Each replicate runs naive, landmark, CCW and sequential trials under 4 physician variants, 3 negative controls, an oracle run, and 2 simulated RCTs. 2,400 replicate files, 0 errors. 16 of 288,000 estimates are missing (sequential trials with physician fixed effects, 4 replicates), and these are dropped.
• Outcome shown. The headline outcome is the disease composite (CLTI or major amputation), whose true effect under the null is exactly 0 (D34). MALE is shown where it adds something.
• Two errors, kept separate (D27). Estimation bias = mean estimate − the method’s own truth. Question gap = the method’s own truth − the reference truth (CCW A vs B1). Total error is the sum.
• Variants shown. “Ignore physician” is V1’s point estimate with the cluster-robust SE (V2). The V1 patient-level SE is in the supplement tables.
• Two open questions came out of this run (Section 6). They affect the landmark results and the negative-control results, so treat those parts as provisional.

1. Aim 1: what each method answers (clean world W0)

Table 2. Disease composite, 5-year risk difference in percentage points, world W0.

Scenario	Method	Reference truth	Own truth	Question gap	Mean estimate	Estimation bias (MCSE)	Empirical SE	Coverage of own truth
null	CCW, A vs B1 (reference)	0.0	0.0	0.0	-0.3	-0.33 (0.26)	2.6	85%
null	CCW, A vs B2	0.0	0.0	0.0	-0.3	-0.33 (0.26)	2.6	85%
null	Sequential trials, ITT	0.0	0.0	0.0	-0.0	-0.02 (0.10)	1.0	94%
null	Landmark at 6 months	0.0	-0.3	-0.3	-0.2	0.14 (0.06)	1.0	97%
null	Naive ‘ever early PVI’	0.0	1.3	1.3	1.1	-0.20 (0.06)	1.2	95%
null	Realistic RCT (n = 240), ITT	0.0	0.0	0.0	-0.1	-0.07 (0.39)	3.9	94%
null	Ideal pragmatic RCT, ITT	0.0	0.0	0.0	-0.1	-0.05 (0.03)	0.3	95%
harm	CCW, A vs B1 (reference)	5.1	5.1	0.0	5.3	0.17 (0.28)	2.8	96%
harm	CCW, A vs B2	5.1	5.2	0.0	5.3	0.17 (0.28)	2.8	96%
harm	Sequential trials, ITT	5.1	5.7	0.6	5.7	-0.01 (0.15)	1.5	91%
harm	Landmark at 6 months	5.1	7.9	2.8	7.8	-0.10 (0.16)	3.6	92%
harm	Naive ‘ever early PVI’	5.1	7.2	2.1	6.9	-0.29 (0.06)	1.6	88%
harm	Realistic RCT (n = 240), ITT	5.1	5.3	0.2	5.5	0.21 (0.43)	4.3	97%
harm	Ideal pragmatic RCT, ITT	5.1	5.2	0.0	5.2	0.04 (0.03)	0.3	95%
benefit_harm	CCW, A vs B1 (reference)	3.1	3.1	0.0	3.3	0.28 (0.29)	2.9	89%
benefit_harm	CCW, A vs B2	3.1	3.0	-0.0	3.3	0.28 (0.29)	2.9	89%
benefit_harm	Sequential trials, ITT	3.1	4.0	0.9	4.2	0.26 (0.11)	1.1	99%
benefit_harm	Landmark at 6 months	3.1	5.3	2.3	5.4	0.03 (0.19)	3.5	95%
benefit_harm	Naive ‘ever early PVI’	3.1	5.7	2.6	5.4	-0.26 (0.07)	1.2	97%
benefit_harm	Realistic RCT (n = 240), ITT	3.1	3.9	0.8	3.8	-0.08 (0.43)	4.3	94%
benefit_harm	Ideal pragmatic RCT, ITT	3.1	3.9	0.8	3.9	0.01 (0.03)	0.3	92%

What it shows.

• Every TTE method is close to unbiased for its own truth in W0 (all |bias| < 0.35 pp). H1a holds.
• The methods answer different questions. Under harm (reference +5.1 pp): sequential trials target +5.7, landmark +7.9 and naive +7.2. So the question gap alone is 0.6–2.8 pp. Under the null, naive has a gap of +1.3 pp from immortal time even with every confounder measured. H1b holds, though the gap for the sequential trials is small.
• CCW is right but imprecise. Its empirical SE is about 2.8 pp at n = 50,000, against about 1.5 pp for sequential trials. Under the null its 95% CI excludes 0 in 15% of replicates (Section 3).
• The realistic RCT (n = 240) is unbiased for its own ITT, but its SE is about 4.2 pp. It detects the 5-point harm in only 25% of replicates.

2. Aim 2: surgery-specific threats

Table 3. Estimation bias (MCSE) against each method’s own truth, percentage points. Harm scenario, disease composite.

Method	Physician variant	W0 Clean	W1 Skill	W1 Skill (rho 0)	W2 Style	W3 Style -> outcome	W4 Deferral	W5 Unmeasured severity	WR Realistic
CCW, A vs B1 (reference)	Ignore physician (cluster SE)	0.2 (0.3)	1.1 (0.3)	0.2 (0.3)	0.2 (0.3)	0.7 (0.3)	-0.0 (0.3)	4.4 (0.2)	7.1 (0.4)
CCW, A vs B1 (reference)	Random intercept	0.2 (0.3)	0.9 (0.3)	0.4 (0.3)	0.1 (0.4)	0.1 (0.4)	0.0 (0.3)	4.4 (0.3)	6.4 (0.4)
CCW, A vs B1 (reference)	Within-physician (FE)	0.1 (0.4)	0.3 (0.4)	0.2 (0.4)	-0.2 (0.5)	-0.3 (0.4)	-0.1 (0.3)	4.4 (0.3)	6.1 (0.4)
Sequential trials, ITT	Ignore physician (cluster SE)	-0.0 (0.1)	1.2 (0.1)	0.1 (0.1)	0.2 (0.1)	1.4 (0.1)	-0.1 (0.1)	4.9 (0.1)	9.3 (0.2)
Sequential trials, ITT	Random intercept	-0.0 (0.2)	0.9 (0.1)	0.1 (0.1)	0.0 (0.2)	0.2 (0.2)	-0.2 (0.1)	5.0 (0.1)	7.4 (0.2)
Sequential trials, ITT	Within-physician (FE)	-0.3 (0.2)	0.2 (0.2)	-0.1 (0.2)	-0.3 (0.2)	-0.5 (0.2)	-0.5 (0.1)	4.9 (0.1)	6.7 (0.2)
Landmark at 6 months	Ignore physician (cluster SE)	-0.1 (0.2)	3.9 (0.4)	1.1 (0.3)	0.1 (0.8)	1.5 (0.7)	-0.0 (0.2)	2.5 (0.4)	1.2 (1.1)
Landmark at 6 months	Random intercept	-0.2 (0.2)	2.7 (0.3)	0.8 (0.3)	-0.3 (0.7)	0.3 (0.5)	0.0 (0.1)	2.6 (0.4)	-0.5 (1.1)
Landmark at 6 months	Within-physician (FE)	-0.7 (0.3)	1.5 (0.5)	0.8 (0.5)	-1.1 (0.7)	-1.0 (0.6)	-0.4 (0.3)	2.5 (0.4)	-1.3 (1.1)
Naive ‘ever early PVI’	Ignore physician (cluster SE)	-0.3 (0.1)	0.5 (0.1)	-0.3 (0.1)	-10.5 (1.0)	-6.4 (0.9)	-0.2 (0.1)	5.5 (0.1)	1.5 (1.0)
Naive ‘ever early PVI’	Random intercept	-0.2 (0.1)	0.4 (0.1)	-0.2 (0.1)	-9.0 (0.9)	-6.1 (0.9)	-0.1 (0.1)	5.6 (0.1)	0.6 (1.0)
Naive ‘ever early PVI’	Within-physician (FE)	-0.9 (0.1)	-0.7 (0.1)	-0.8 (0.1)	-11.5 (1.0)	-8.9 (0.9)	-1.0 (0.1)	5.3 (0.1)	-1.0 (1.0)

Table 3b. Total error against the reference truth (CCW A vs B1), percentage points. Harm scenario, disease composite.

Method	Physician variant	W0 Clean	W1 Skill	W1 Skill (rho 0)	W2 Style	W3 Style -> outcome	W4 Deferral	W5 Unmeasured severity	WR Realistic
CCW, A vs B1 (reference)	Ignore physician (cluster SE)	0.2	1.1	0.2	0.2	0.7	-0.0	4.4	7.1
CCW, A vs B1 (reference)	Random intercept	0.2	0.9	0.4	0.1	0.1	0.0	4.4	6.4
CCW, A vs B1 (reference)	Within-physician (FE)	0.1	0.3	0.2	-0.2	-0.3	-0.1	4.4	6.1
Sequential trials, ITT	Ignore physician (cluster SE)	0.6	2.0	0.9	0.8	2.0	0.5	5.5	10.0
Sequential trials, ITT	Random intercept	0.6	1.7	0.9	0.6	0.8	0.5	5.6	8.2
Sequential trials, ITT	Within-physician (FE)	0.3	1.0	0.7	0.3	0.1	0.1	5.5	7.4
Landmark at 6 months	Ignore physician (cluster SE)	2.7	16.5	14.1	3.2	3.5	2.4	5.6	9.8
Landmark at 6 months	Random intercept	2.7	15.4	13.7	2.9	2.2	2.4	5.6	8.1
Landmark at 6 months	Within-physician (FE)	2.2	14.2	13.7	2.0	1.0	2.0	5.5	7.3
Naive ‘ever early PVI’	Ignore physician (cluster SE)	1.8	3.1	2.1	2.1	3.2	1.7	7.6	11.8
Naive ‘ever early PVI’	Random intercept	1.9	3.0	2.2	3.6	3.5	1.8	7.7	10.9
Naive ‘ever early PVI’	Within-physician (FE)	1.2	1.9	1.6	1.1	0.7	0.9	7.4	9.3

What it shows.

• Surgeon skill (W1). CCW and sequential trials stay within about 1 pp, and the FE variant brings them to 0.2–0.3 pp. The landmark is badly off (total error about 14–16 pp). Almost all of that is question gap, not estimation bias, and Section 6 (Q1) explains why.
• Practice style (W2). It only harms the naive design (bias −9 to −12 pp). The TTE designs absorb style through their time-varying PVI models.
• Style that also changes the outcome coding (W3). It biases landmark and sequential trials by about 1.5 pp when the physician is ignored. A random intercept or FE removes most of it, which supports H2b.
• Deferral / crossover (W4). No design bias. The TTE designs handle crossover by design.
• Unmeasured severity (W5). It biases every observational design by about 2.5–5.5 pp, and no physician variant helps (H2c holds).
• Realistic world (WR). CCW is biased by +6 to +7 pp and sequential trials by +7 to +9 pp. FE helps only a little. Unmeasured severity dominates.

3. False alarms under the null (headline for clinicians)

What it shows.

• In the clean, skill and deferral worlds, landmark, sequential trials and naive are near 5%. CCW is at 10–15% in W0/W1, mainly because its SE is slightly underestimated in the null scenario (model/empirical SE 0.86 in W0) and its estimate sits slightly low (−0.33 pp, 1.3 MCSE). The bootstrap check (D28) is meant to settle this.
• Style that changes outcome coding (W3) pushes naive to 51–55% and sequential trials to 25% when the physician is ignored. A random intercept or FE brings that back to 8–16%.
• Unmeasured severity (W5, WR) gives 80–100% false alarms for landmark, sequential trials and naive. CCW stays at 15–24%, but only because its SE is wide. FE lowers the landmark and sequential rates in WR (31% and 60%).
• MALE under the sharp null: +14 pp for CCW, purely because only treated patients can have a repeat revascularization. Every design “detects harm” on MALE in 93–100% of replicates.

4. Aim 3: do negative controls detect bias?

Table 4. Sensitivity / specificity of each negative control for MALE bias > 1 pp. A cell (world × scenario × method × variant) counts as biased when its mean MALE bias exceeds 1 pp; a replicate is flagged when the control’s 95% CI excludes 0. ‘–’: no biased (or no clean) cells in that world.

control	W0 Clean	W1 Skill	W1 Skill (rho 0)	W2 Style	W3 Style -> outcome	W4 Deferral	W5 Unmeasured severity	WR Realistic	All worlds
NCO-1 (hip fracture / pneumonia)	–	11% / 94%	19% / 89%	13% / 87%	13% / 89%	12% / 92%	10% / –	12% / 88%	12% / 90%
NCO-2 (vein ablation)	–	25% / 78%	7% / 75%	54% / 45%	52% / 26%	11% / 74%	42% / –	67% / 92%	48% / 70%
NCE (early low-value procedure)	–	4% / 94%	6% / 96%	5% / 95%	9% / 88%	7% / 94%	6% / –	9% / 93%	7% / 94%
Any of the three	–	37% / 72%	30% / 65%	63% / 36%	61% / 20%	25% / 65%	50% / –	73% / 78%	57% / 61%

What it shows (provisional, see Q2).

• NCO-1 almost never flags (sensitivity about 12%), even with unmeasured severity (W5). In the current DGP, NCO-1 depends on frailty, smoking and age but not on claudication severity, so it cannot see the main source of bias. H3a fails, by construction.
• NCO-2 is the working detector (48% sensitivity overall, 65–67% in WR). It also fires when style does no harm (specificity 26–45% in W2/W3), which supports H3b.
• The NCE almost never flags (about 5–9%). It is adjusted for early PVI (D36), and it shares style and frailty, not severity.
• Bias hides behind clean controls. In WR, the cells with clean negative controls still have a median |MALE bias| of 8.5 pp (H3c).

5. Simulated RCTs

Table 5. Simulated trials, disease composite (pp).

World	Scenario	Trial	Reference	Own ITT truth	Mean estimate	Empirical SE	Power (CI excludes 0)
W0 Clean	benefit_harm	Ideal RCT, as-treated	3.1	NA	4.9	0.3	100%
W0 Clean	benefit_harm	Realistic RCT, as-treated	3.1	NA	4.7	4.1	19%
W0 Clean	benefit_harm	Ideal pragmatic RCT, ITT	3.1	3.9	3.9	0.3	100%
W0 Clean	benefit_harm	Realistic RCT (n = 240), ITT	3.1	3.9	3.8	4.3	13%
W0 Clean	harm	Ideal RCT, as-treated	5.1	NA	6.5	0.3	100%
W0 Clean	harm	Realistic RCT, as-treated	5.1	NA	6.7	4.0	29%
W0 Clean	harm	Ideal pragmatic RCT, ITT	5.1	5.2	5.2	0.3	100%
W0 Clean	harm	Realistic RCT (n = 240), ITT	5.1	5.3	5.5	4.3	25%
W1 Skill	benefit_harm	Ideal RCT, as-treated	7.9	NA	10.7	0.8	100%
W1 Skill	benefit_harm	Realistic RCT, as-treated	7.9	NA	-2.0	4.0	10%
W1 Skill	benefit_harm	Ideal pragmatic RCT, ITT	7.9	8.7	8.7	0.7	100%
W1 Skill	benefit_harm	Realistic RCT (n = 240), ITT	7.9	-1.4	-2.1	4.0	9%
W1 Skill	harm	Ideal RCT, as-treated	7.2	NA	9.1	0.5	100%
W1 Skill	harm	Realistic RCT, as-treated	7.2	NA	2.3	4.4	6%
W1 Skill	harm	Ideal pragmatic RCT, ITT	7.2	7.3	7.3	0.4	100%
W1 Skill	harm	Realistic RCT (n = 240), ITT	7.2	2.1	2.0	4.5	8%
W1 Skill (rho 0)	benefit_harm	Ideal RCT, as-treated	7.9	NA	10.7	0.7	100%
W1 Skill (rho 0)	benefit_harm	Realistic RCT, as-treated	7.9	NA	-1.7	3.4	9%
W1 Skill (rho 0)	benefit_harm	Ideal pragmatic RCT, ITT	7.9	8.8	8.8	0.6	100%
W1 Skill (rho 0)	benefit_harm	Realistic RCT (n = 240), ITT	7.9	-1.1	-1.6	3.4	6%
W1 Skill (rho 0)	harm	Ideal RCT, as-treated	7.1	NA	8.9	0.4	100%
W1 Skill (rho 0)	harm	Realistic RCT, as-treated	7.1	NA	2.1	4.7	10%
W1 Skill (rho 0)	harm	Ideal pragmatic RCT, ITT	7.1	7.3	7.3	0.4	100%
W1 Skill (rho 0)	harm	Realistic RCT (n = 240), ITT	7.1	2.3	1.8	4.7	12%
W2 Style	benefit_harm	Ideal RCT, as-treated	3.0	NA	4.9	0.3	100%
W2 Style	benefit_harm	Realistic RCT, as-treated	3.0	NA	4.8	4.5	18%
W2 Style	benefit_harm	Ideal pragmatic RCT, ITT	3.0	3.9	4.0	0.3	100%
W2 Style	benefit_harm	Realistic RCT (n = 240), ITT	3.0	3.9	4.3	4.3	18%
W2 Style	harm	Ideal RCT, as-treated	5.1	NA	6.4	0.3	100%
W2 Style	harm	Realistic RCT, as-treated	5.1	NA	5.9	4.6	25%
W2 Style	harm	Ideal pragmatic RCT, ITT	5.1	5.2	5.2	0.3	100%
W2 Style	harm	Realistic RCT (n = 240), ITT	5.1	5.4	5.3	4.5	22%
W3 Style -> outcome	benefit_harm	Ideal RCT, as-treated	3.0	NA	4.8	0.3	100%
W3 Style -> outcome	benefit_harm	Realistic RCT, as-treated	3.0	NA	4.8	4.4	26%
W3 Style -> outcome	benefit_harm	Ideal pragmatic RCT, ITT	3.0	3.8	3.9	0.3	100%
W3 Style -> outcome	benefit_harm	Realistic RCT (n = 240), ITT	3.0	3.9	4.0	4.0	15%
W3 Style -> outcome	harm	Ideal RCT, as-treated	5.0	NA	6.3	0.3	100%
W3 Style -> outcome	harm	Realistic RCT, as-treated	5.0	NA	6.0	4.6	31%
W3 Style -> outcome	harm	Ideal pragmatic RCT, ITT	5.0	5.0	5.1	0.3	100%
W3 Style -> outcome	harm	Realistic RCT (n = 240), ITT	5.0	5.3	5.9	4.4	28%
W4 Deferral	benefit_harm	Ideal RCT, as-treated	3.3	NA	5.1	0.3	100%
W4 Deferral	benefit_harm	Realistic RCT, as-treated	3.3	NA	4.6	4.8	17%
W4 Deferral	benefit_harm	Ideal pragmatic RCT, ITT	3.3	4.1	4.1	0.3	100%
W4 Deferral	benefit_harm	Realistic RCT (n = 240), ITT	3.3	4.0	4.1	4.7	17%
W4 Deferral	harm	Ideal RCT, as-treated	4.8	NA	6.2	0.3	100%
W4 Deferral	harm	Realistic RCT, as-treated	4.8	NA	6.4	4.3	25%
W4 Deferral	harm	Ideal pragmatic RCT, ITT	4.8	4.9	4.9	0.3	100%
W4 Deferral	harm	Realistic RCT (n = 240), ITT	4.8	5.2	5.3	3.9	19%
W5 Unmeasured severity	benefit_harm	Ideal RCT, as-treated	3.1	NA	4.9	0.3	100%
W5 Unmeasured severity	benefit_harm	Realistic RCT, as-treated	3.1	NA	4.6	4.3	18%
W5 Unmeasured severity	benefit_harm	Ideal pragmatic RCT, ITT	3.1	3.9	3.9	0.3	100%
W5 Unmeasured severity	benefit_harm	Realistic RCT (n = 240), ITT	3.1	3.9	3.9	4.3	13%
W5 Unmeasured severity	harm	Ideal RCT, as-treated	5.1	NA	6.4	0.4	100%
W5 Unmeasured severity	harm	Realistic RCT, as-treated	5.1	NA	6.2	4.8	29%
W5 Unmeasured severity	harm	Ideal pragmatic RCT, ITT	5.1	5.2	5.1	0.3	100%
W5 Unmeasured severity	harm	Realistic RCT (n = 240), ITT	5.1	5.3	5.9	4.7	33%
WR Realistic	benefit_harm	Ideal RCT, as-treated	7.7	NA	10.6	0.8	100%
WR Realistic	benefit_harm	Realistic RCT, as-treated	7.7	NA	-1.6	3.7	8%
WR Realistic	benefit_harm	Ideal pragmatic RCT, ITT	7.7	8.4	8.4	0.6	100%
WR Realistic	benefit_harm	Realistic RCT (n = 240), ITT	7.7	-1.4	-1.3	3.7	6%
WR Realistic	harm	Ideal RCT, as-treated	6.9	NA	8.8	0.5	100%
WR Realistic	harm	Realistic RCT, as-treated	6.9	NA	1.8	4.4	11%
WR Realistic	harm	Ideal pragmatic RCT, ITT	6.9	7.0	7.0	0.4	100%
WR Realistic	harm	Realistic RCT (n = 240), ITT	6.9	2.1	1.7	4.2	9%

• Surgeon selection changes the answer. In WR, a realistic trial recruits hospital-based, top-third-skill, low-style surgeons. Its own ITT truth is +2.1 pp under harm and −1.4 pp under benefit-then-harm, while the population effects are +6.9 and +7.7. A well-run trial answers a question about selected surgeons (H1c).
• Small trials are uninformative. With n = 240 the SE is about 4 pp, giving 6–29% power against effects of 5–8 pp.
• The ideal pragmatic RCT (n = 50,000) recovers its truth with an SE of about 0.3–0.6 pp.

6. Open questions raised by the draft run

Q1. Landmark adjusts for severity at month 5, after the PVI. As specified in D13, the landmark propensity model uses covariates at diagnosis and at month W−1. For treated patients, month-5 severity is already changed by the PVI (relief, then faster progression), so it is a mediator. Conditioning on it gives extreme weights (effective treated sample about 110–140) and a large own-truth shift when the harm varies between patients (W1: own truth about 20 pp vs a reference of 7 pp). A check on 20 oracle replicates gave these landmark estimates:

World (harm)	Adjust for month-5 severity	Baseline covariates only	Reference
W0	8.6 (SD 3.4)	5.6 (SD 1.4)	5.1
W1	14.6 (SD 4.3)	8.1 (SD 1.6)	7.2

Q2. NCO-1 does not depend on severity. D32 says NCO-1 “shares the latent patient frailty, severity and smoking”, but the DGP’s NCO-1 model has no severity term. That is why it misses the W5/WR bias.

Also pending: the physician-cluster bootstrap check of SEs (D28). Model-to-empirical SE ratios are near 1 for CCW (0.96–1.07, except WR 0.87). They are 0.83–0.92 for landmark and sequential trials in W0, and 0.58 for landmark in W1.

Supplement: full performance table

outcome	scenario	world	method	variant	est	own	ref	bias	mcse	gap	emp_se	se_ratio	cover	reject0
disease	benefit_harm	W0	Naive ‘ever early PVI’	V1_ignore	5.43	5.69	3.05	-0.26	0.07	2.64	1.22	1.15	0.97	1.00
disease	benefit_harm	W0	Naive ‘ever early PVI’	V2_cluster	5.43	5.69	3.05	-0.26	0.07	2.64	1.22	1.15	0.97	1.00
disease	benefit_harm	W0	Naive ‘ever early PVI’	V3_random	5.55	5.69	3.05	-0.14	0.07	2.64	1.29	1.11	0.96	1.00
disease	benefit_harm	W0	Naive ‘ever early PVI’	V4_within	4.92	5.69	3.05	-0.78	0.13	2.64	1.80	0.95	0.84	0.89
disease	benefit_harm	W0	Landmark at 6 months	V1_ignore	5.38	5.35	3.05	0.03	0.19	2.30	3.52	1.10	0.95	0.24
disease	benefit_harm	W0	Landmark at 6 months	V2_cluster	5.38	5.35	3.05	0.03	0.19	2.30	3.52	1.10	0.95	0.24
disease	benefit_harm	W0	Landmark at 6 months	V3_random	5.38	5.35	3.05	0.03	0.19	2.30	3.55	1.09	0.95	0.24
disease	benefit_harm	W0	Landmark at 6 months	V4_within	5.87	5.35	3.05	0.52	0.45	2.30	6.47	0.83	0.90	0.14
disease	benefit_harm	W0	Sequential trials, ITT	V1_ignore	4.25	3.98	3.05	0.26	0.11	0.93	1.07	1.15	0.99	0.96
disease	benefit_harm	W0	Sequential trials, ITT	V2_cluster	4.25	3.98	3.05	0.26	0.11	0.93	1.07	1.15	0.99	0.96
disease	benefit_harm	W0	Sequential trials, ITT	V3_random	4.22	3.98	3.05	0.24	0.11	0.93	1.13	1.10	0.99	0.96
disease	benefit_harm	W0	Sequential trials, ITT	V4_within	4.05	3.98	3.05	0.07	0.17	0.93	1.70	0.87	0.89	0.79
disease	benefit_harm	W0	CCW, A vs B2	V1_ignore	3.31	3.03	3.05	0.28	0.29	-0.02	2.88	0.93	0.87	0.20
disease	benefit_harm	W0	CCW, A vs B2	V2_cluster	3.31	3.03	3.05	0.28	0.29	-0.02	2.88	0.93	0.89	0.18
disease	benefit_harm	W0	CCW, A vs B2	V3_random	3.36	3.03	3.05	0.33	0.28	-0.02	2.85	0.94	0.90	0.19
disease	benefit_harm	W0	CCW, A vs B2	V4_within	3.28	3.03	3.05	0.25	0.31	-0.02	3.12	0.99	0.92	0.15
disease	benefit_harm	W0	CCW, A vs B1 (reference)	V1_ignore	3.33	3.05	3.05	0.28	0.29	0.00	2.88	0.93	0.87	0.20
disease	benefit_harm	W0	CCW, A vs B1 (reference)	V2_cluster	3.33	3.05	3.05	0.28	0.29	0.00	2.88	0.92	0.89	0.18
disease	benefit_harm	W0	CCW, A vs B1 (reference)	V3_random	3.38	3.05	3.05	0.33	0.28	0.00	2.85	0.94	0.91	0.19
disease	benefit_harm	W0	CCW, A vs B1 (reference)	V4_within	3.29	3.05	3.05	0.24	0.31	0.00	3.12	0.99	0.92	0.15
disease	benefit_harm	W1	Naive ‘ever early PVI’	V1_ignore	12.25	10.68	7.94	1.57	0.10	2.73	1.69	0.94	0.83	1.00
disease	benefit_harm	W1	Naive ‘ever early PVI’	V2_cluster	12.25	10.68	7.94	1.57	0.10	2.73	1.69	1.04	0.91	1.00
disease	benefit_harm	W1	Naive ‘ever early PVI’	V3_random	11.84	10.68	7.94	1.16	0.08	2.73	1.63	1.05	0.92	1.00
disease	benefit_harm	W1	Naive ‘ever early PVI’	V4_within	10.51	10.68	7.94	-0.17	0.12	2.73	1.87	1.06	0.98	1.00
disease	benefit_harm	W1	Landmark at 6 months	V1_ignore	11.96	8.86	7.94	3.10	0.24	0.91	5.33	0.82	0.85	0.82
disease	benefit_harm	W1	Landmark at 6 months	V2_cluster	11.96	8.86	7.94	3.10	0.24	0.91	5.33	0.84	0.86	0.81
disease	benefit_harm	W1	Landmark at 6 months	V3_random	11.71	8.86	7.94	2.85	0.23	0.91	5.26	0.84	0.87	0.81
disease	benefit_harm	W1	Landmark at 6 months	V4_within	10.13	8.86	7.94	1.27	0.44	0.91	6.85	0.76	0.85	0.54
disease	benefit_harm	W1	Sequential trials, ITT	V1_ignore	11.22	9.26	7.94	1.97	0.16	1.31	1.63	0.90	0.73	1.00
disease	benefit_harm	W1	Sequential trials, ITT	V2_cluster	11.22	9.26	7.94	1.97	0.16	1.31	1.63	1.02	0.83	1.00
disease	benefit_harm	W1	Sequential trials, ITT	V3_random	10.67	9.26	7.94	1.41	0.16	1.31	1.55	1.04	0.90	1.00
disease	benefit_harm	W1	Sequential trials, ITT	V4_within	9.78	9.26	7.94	0.52	0.17	1.31	1.74	1.05	0.97	1.00
disease	benefit_harm	W1	CCW, A vs B2	V1_ignore	9.63	7.99	7.94	1.64	0.37	0.04	3.72	0.87	0.90	0.89
disease	benefit_harm	W1	CCW, A vs B2	V2_cluster	9.63	7.99	7.94	1.64	0.37	0.04	3.72	0.89	0.91	0.89
disease	benefit_harm	W1	CCW, A vs B2	V3_random	9.17	7.99	7.94	1.18	0.37	0.04	3.70	0.87	0.93	0.86
disease	benefit_harm	W1	CCW, A vs B2	V4_within	8.52	7.99	7.94	0.53	0.43	0.04	4.34	0.84	0.87	0.66
disease	benefit_harm	W1	CCW, A vs B1 (reference)	V1_ignore	9.58	7.94	7.94	1.64	0.37	0.00	3.72	0.87	0.90	0.88
disease	benefit_harm	W1	CCW, A vs B1 (reference)	V2_cluster	9.58	7.94	7.94	1.64	0.37	0.00	3.72	0.89	0.92	0.89
disease	benefit_harm	W1	CCW, A vs B1 (reference)	V3_random	9.12	7.94	7.94	1.18	0.37	0.00	3.70	0.87	0.93	0.86
disease	benefit_harm	W1	CCW, A vs B1 (reference)	V4_within	8.46	7.94	7.94	0.52	0.43	0.00	4.34	0.84	0.87	0.65
disease	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V1_ignore	10.48	10.72	7.92	-0.23	0.09	2.80	1.67	0.92	0.94	1.00
disease	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V2_cluster	10.48	10.72	7.92	-0.23	0.09	2.80	1.67	1.00	0.95	1.00
disease	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V3_random	10.62	10.72	7.92	-0.09	0.08	2.80	1.74	0.97	0.95	1.00
disease	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V4_within	9.98	10.72	7.92	-0.74	0.12	2.80	2.22	0.93	0.88	1.00
disease	benefit_harm	W1_rho0	Landmark at 6 months	V1_ignore	11.09	10.12	7.92	0.97	0.24	2.21	5.20	0.89	0.95	0.79
disease	benefit_harm	W1_rho0	Landmark at 6 months	V2_cluster	11.09	10.12	7.92	0.97	0.24	2.21	5.20	0.91	0.95	0.79
disease	benefit_harm	W1_rho0	Landmark at 6 months	V3_random	11.03	10.12	7.92	0.91	0.23	2.21	5.19	0.90	0.94	0.79
disease	benefit_harm	W1_rho0	Landmark at 6 months	V4_within	10.22	10.12	7.92	0.10	0.58	2.21	7.21	0.85	0.82	0.46
disease	benefit_harm	W1_rho0	Sequential trials, ITT	V1_ignore	9.36	9.28	7.92	0.08	0.16	1.36	1.56	0.91	0.95	1.00
disease	benefit_harm	W1_rho0	Sequential trials, ITT	V2_cluster	9.36	9.28	7.92	0.08	0.16	1.36	1.56	1.00	0.95	1.00
disease	benefit_harm	W1_rho0	Sequential trials, ITT	V3_random	9.36	9.28	7.92	0.08	0.16	1.36	1.63	0.96	0.95	1.00
disease	benefit_harm	W1_rho0	Sequential trials, ITT	V4_within	9.14	9.28	7.92	-0.14	0.21	1.36	2.07	0.90	0.92	1.00
disease	benefit_harm	W1_rho0	CCW, A vs B2	V1_ignore	7.81	7.94	7.92	-0.13	0.30	0.02	3.04	1.01	0.95	0.82
disease	benefit_harm	W1_rho0	CCW, A vs B2	V2_cluster	7.81	7.94	7.92	-0.13	0.30	0.02	3.04	1.02	0.95	0.80
disease	benefit_harm	W1_rho0	CCW, A vs B2	V3_random	7.91	7.94	7.92	-0.03	0.33	0.02	3.34	0.95	0.93	0.76
disease	benefit_harm	W1_rho0	CCW, A vs B2	V4_within	8.05	7.94	7.92	0.11	0.45	0.02	4.47	0.86	0.91	0.60
disease	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	7.78	7.92	7.92	-0.14	0.30	0.00	3.04	1.01	0.95	0.79
disease	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	7.78	7.92	7.92	-0.14	0.30	0.00	3.04	1.02	0.95	0.79
disease	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V3_random	7.88	7.92	7.92	-0.04	0.33	0.00	3.34	0.95	0.93	0.75
disease	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V4_within	8.03	7.92	7.92	0.11	0.45	0.00	4.47	0.86	0.91	0.60
disease	benefit_harm	W2	Naive ‘ever early PVI’	V1_ignore	5.70	14.36	3.05	-8.66	0.99	11.31	1.37	1.03	0.00	1.00
disease	benefit_harm	W2	Naive ‘ever early PVI’	V2_cluster	5.70	14.36	3.05	-8.66	0.99	11.31	1.37	1.03	0.00	1.00
disease	benefit_harm	W2	Naive ‘ever early PVI’	V3_random	6.98	14.36	3.05	-7.38	0.96	11.31	2.11	1.14	0.15	0.94
disease	benefit_harm	W2	Naive ‘ever early PVI’	V4_within	4.65	14.36	3.05	-9.71	1.03	11.31	2.40	1.05	0.06	0.54
disease	benefit_harm	W2	Landmark at 6 months	V1_ignore	4.88	4.29	3.05	0.59	0.83	1.24	3.49	1.06	0.94	0.18
disease	benefit_harm	W2	Landmark at 6 months	V2_cluster	4.88	4.29	3.05	0.59	0.83	1.24	3.49	1.05	0.95	0.18
disease	benefit_harm	W2	Landmark at 6 months	V3_random	5.23	4.29	3.05	0.94	0.81	1.24	3.84	1.02	0.97	0.16
disease	benefit_harm	W2	Landmark at 6 months	V4_within	4.95	4.29	3.05	0.66	0.88	1.24	5.55	0.96	0.91	0.05
disease	benefit_harm	W2	Sequential trials, ITT	V1_ignore	4.39	3.98	3.05	0.41	0.13	0.93	1.28	0.96	0.92	0.98
disease	benefit_harm	W2	Sequential trials, ITT	V2_cluster	4.39	3.98	3.05	0.41	0.13	0.93	1.28	0.96	0.91	0.99
disease	benefit_harm	W2	Sequential trials, ITT	V3_random	4.15	3.98	3.05	0.18	0.17	0.93	1.65	1.02	0.97	0.74
disease	benefit_harm	W2	Sequential trials, ITT	V4_within	3.88	3.98	3.05	-0.10	0.19	0.93	1.86	1.01	0.94	0.49
disease	benefit_harm	W2	CCW, A vs B2	V1_ignore	3.13	3.03	3.05	0.09	0.25	-0.02	2.45	1.13	0.96	0.11
disease	benefit_harm	W2	CCW, A vs B2	V2_cluster	3.13	3.03	3.05	0.09	0.25	-0.02	2.45	1.12	0.97	0.14
disease	benefit_harm	W2	CCW, A vs B2	V3_random	3.50	3.03	3.05	0.47	0.32	-0.02	3.16	1.14	0.92	0.07
disease	benefit_harm	W2	CCW, A vs B2	V4_within	3.44	3.03	3.05	0.41	0.40	-0.02	3.95	1.05	0.90	0.05
disease	benefit_harm	W2	CCW, A vs B1 (reference)	V1_ignore	3.15	3.05	3.05	0.10	0.25	0.00	2.45	1.13	0.96	0.11
disease	benefit_harm	W2	CCW, A vs B1 (reference)	V2_cluster	3.15	3.05	3.05	0.10	0.25	0.00	2.45	1.12	0.97	0.14
disease	benefit_harm	W2	CCW, A vs B1 (reference)	V3_random	3.52	3.05	3.05	0.47	0.32	0.00	3.16	1.14	0.92	0.07
disease	benefit_harm	W2	CCW, A vs B1 (reference)	V4_within	3.44	3.05	3.05	0.39	0.40	0.00	3.97	1.05	0.90	0.05
disease	benefit_harm	W3	Naive ‘ever early PVI’	V1_ignore	6.92	14.67	2.98	-7.75	0.92	11.69	1.61	0.92	0.00	1.00
disease	benefit_harm	W3	Naive ‘ever early PVI’	V2_cluster	6.92	14.67	2.98	-7.75	0.92	11.69	1.61	0.91	0.00	1.00
disease	benefit_harm	W3	Naive ‘ever early PVI’	V3_random	7.38	14.67	2.98	-7.29	0.86	11.69	2.70	0.90	0.23	0.93
disease	benefit_harm	W3	Naive ‘ever early PVI’	V4_within	4.69	14.67	2.98	-9.97	0.92	11.69	2.78	0.93	0.08	0.50
disease	benefit_harm	W3	Landmark at 6 months	V1_ignore	5.81	4.11	2.98	1.70	0.56	1.13	3.83	1.04	0.98	0.23
disease	benefit_harm	W3	Landmark at 6 months	V2_cluster	5.81	4.11	2.98	1.70	0.56	1.13	3.83	1.04	0.98	0.26
disease	benefit_harm	W3	Landmark at 6 months	V3_random	5.53	4.11	2.98	1.42	0.49	1.13	3.73	1.07	0.95	0.17
disease	benefit_harm	W3	Landmark at 6 months	V4_within	4.54	4.11	2.98	0.43	0.59	1.13	5.28	0.92	0.89	0.11
disease	benefit_harm	W3	Sequential trials, ITT	V1_ignore	5.52	3.88	2.98	1.64	0.14	0.90	1.41	0.92	0.74	1.00
disease	benefit_harm	W3	Sequential trials, ITT	V2_cluster	5.52	3.88	2.98	1.64	0.14	0.90	1.41	0.91	0.74	1.00
disease	benefit_harm	W3	Sequential trials, ITT	V3_random	4.44	3.88	2.98	0.56	0.19	0.90	1.94	0.90	0.95	0.75
disease	benefit_harm	W3	Sequential trials, ITT	V4_within	3.85	3.88	2.98	-0.03	0.23	0.90	2.25	0.86	0.90	0.52
disease	benefit_harm	W3	CCW, A vs B2	V1_ignore	3.70	2.96	2.98	0.74	0.30	-0.01	3.00	0.98	0.96	0.23
disease	benefit_harm	W3	CCW, A vs B2	V2_cluster	3.70	2.96	2.98	0.74	0.30	-0.01	3.00	0.99	0.96	0.24
disease	benefit_harm	W3	CCW, A vs B2	V3_random	3.22	2.96	2.98	0.26	0.40	-0.01	4.01	0.95	0.88	0.07
disease	benefit_harm	W3	CCW, A vs B2	V4_within	2.83	2.96	2.98	-0.13	0.47	-0.01	4.74	0.90	0.82	0.06
disease	benefit_harm	W3	CCW, A vs B1 (reference)	V1_ignore	3.71	2.98	2.98	0.73	0.30	0.00	3.00	0.98	0.96	0.22
disease	benefit_harm	W3	CCW, A vs B1 (reference)	V2_cluster	3.71	2.98	2.98	0.73	0.30	0.00	3.00	0.99	0.96	0.23
disease	benefit_harm	W3	CCW, A vs B1 (reference)	V3_random	3.23	2.98	2.98	0.25	0.40	0.00	4.02	0.95	0.88	0.07
disease	benefit_harm	W3	CCW, A vs B1 (reference)	V4_within	2.87	2.98	2.98	-0.11	0.47	0.00	4.75	0.90	0.82	0.07
disease	benefit_harm	W4	Naive ‘ever early PVI’	V1_ignore	5.47	5.75	3.29	-0.27	0.08	2.45	1.34	1.04	0.93	0.99
disease	benefit_harm	W4	Naive ‘ever early PVI’	V2_cluster	5.47	5.75	3.29	-0.27	0.08	2.45	1.34	1.04	0.92	0.99
disease	benefit_harm	W4	Naive ‘ever early PVI’	V3_random	5.63	5.75	3.29	-0.11	0.07	2.45	1.39	1.04	0.94	0.99
disease	benefit_harm	W4	Naive ‘ever early PVI’	V4_within	5.01	5.75	3.29	-0.73	0.13	2.45	1.63	1.06	0.88	0.92
disease	benefit_harm	W4	Landmark at 6 months	V1_ignore	4.93	4.77	3.29	0.16	0.14	1.48	3.43	1.03	0.94	0.22
disease	benefit_harm	W4	Landmark at 6 months	V2_cluster	4.93	4.77	3.29	0.16	0.14	1.48	3.43	1.03	0.95	0.23
disease	benefit_harm	W4	Landmark at 6 months	V3_random	4.90	4.77	3.29	0.13	0.13	1.48	3.42	1.03	0.95	0.23
disease	benefit_harm	W4	Landmark at 6 months	V4_within	4.10	4.77	3.29	-0.67	0.28	1.48	4.42	0.97	0.82	0.09
disease	benefit_harm	W4	Sequential trials, ITT	V1_ignore	4.32	4.22	3.29	0.10	0.12	0.93	1.19	1.04	0.94	0.94
disease	benefit_harm	W4	Sequential trials, ITT	V2_cluster	4.32	4.22	3.29	0.10	0.12	0.93	1.19	1.04	0.94	0.95
disease	benefit_harm	W4	Sequential trials, ITT	V3_random	4.34	4.22	3.29	0.13	0.12	0.93	1.24	1.02	0.94	0.95
disease	benefit_harm	W4	Sequential trials, ITT	V4_within	4.20	4.22	3.29	-0.02	0.15	0.93	1.54	0.97	0.93	0.85
disease	benefit_harm	W4	CCW, A vs B2	V1_ignore	2.86	3.04	3.29	-0.18	0.26	-0.25	2.64	0.98	0.91	0.17
disease	benefit_harm	W4	CCW, A vs B2	V2_cluster	2.86	3.04	3.29	-0.18	0.26	-0.25	2.64	0.97	0.91	0.17
disease	benefit_harm	W4	CCW, A vs B2	V3_random	2.92	3.04	3.29	-0.12	0.27	-0.25	2.74	0.95	0.91	0.17
disease	benefit_harm	W4	CCW, A vs B2	V4_within	2.65	3.04	3.29	-0.39	0.32	-0.25	3.20	0.92	0.87	0.13
disease	benefit_harm	W4	CCW, A vs B1 (reference)	V1_ignore	3.12	3.29	3.29	-0.17	0.26	0.00	2.64	0.98	0.91	0.18
disease	benefit_harm	W4	CCW, A vs B1 (reference)	V2_cluster	3.12	3.29	3.29	-0.17	0.26	0.00	2.64	0.97	0.91	0.18
disease	benefit_harm	W4	CCW, A vs B1 (reference)	V3_random	3.14	3.29	3.29	-0.16	0.27	0.00	2.73	0.95	0.91	0.20
disease	benefit_harm	W4	CCW, A vs B1 (reference)	V4_within	2.91	3.29	3.29	-0.38	0.32	0.00	3.19	0.92	0.87	0.14
disease	benefit_harm	W5	Naive ‘ever early PVI’	V1_ignore	10.21	5.18	3.05	5.03	0.15	2.13	1.26	0.89	0.00	1.00
disease	benefit_harm	W5	Naive ‘ever early PVI’	V2_cluster	10.21	5.18	3.05	5.03	0.15	2.13	1.26	0.89	0.01	1.00
disease	benefit_harm	W5	Naive ‘ever early PVI’	V3_random	10.27	5.18	3.05	5.09	0.14	2.13	1.28	0.89	0.00	1.00
disease	benefit_harm	W5	Naive ‘ever early PVI’	V4_within	10.02	5.18	3.05	4.84	0.15	2.13	1.47	0.94	0.06	1.00
disease	benefit_harm	W5	Landmark at 6 months	V1_ignore	10.29	5.09	3.05	5.19	0.40	2.04	1.29	0.89	0.01	1.00
disease	benefit_harm	W5	Landmark at 6 months	V2_cluster	10.29	5.09	3.05	5.19	0.40	2.04	1.29	0.89	0.01	1.00
disease	benefit_harm	W5	Landmark at 6 months	V3_random	10.30	5.09	3.05	5.20	0.40	2.04	1.30	0.90	0.00	1.00
disease	benefit_harm	W5	Landmark at 6 months	V4_within	10.32	5.09	3.05	5.22	0.41	2.04	1.54	0.92	0.04	1.00
disease	benefit_harm	W5	Sequential trials, ITT	V1_ignore	8.37	3.98	3.05	4.39	0.12	0.93	1.22	0.91	0.00	1.00
disease	benefit_harm	W5	Sequential trials, ITT	V2_cluster	8.37	3.98	3.05	4.39	0.12	0.93	1.22	0.91	0.00	1.00
disease	benefit_harm	W5	Sequential trials, ITT	V3_random	8.34	3.98	3.05	4.36	0.13	0.93	1.26	0.90	0.01	1.00
disease	benefit_harm	W5	Sequential trials, ITT	V4_within	8.29	3.98	3.05	4.31	0.15	0.93	1.47	0.92	0.12	1.00
disease	benefit_harm	W5	CCW, A vs B2	V1_ignore	6.81	3.03	3.05	3.77	0.25	-0.02	2.46	0.97	0.75	0.88
disease	benefit_harm	W5	CCW, A vs B2	V2_cluster	6.81	3.03	3.05	3.77	0.25	-0.02	2.46	0.97	0.74	0.88
disease	benefit_harm	W5	CCW, A vs B2	V3_random	6.83	3.03	3.05	3.80	0.25	-0.02	2.54	0.96	0.76	0.87
disease	benefit_harm	W5	CCW, A vs B2	V4_within	6.86	3.03	3.05	3.83	0.30	-0.02	3.03	0.96	0.82	0.71
disease	benefit_harm	W5	CCW, A vs B1 (reference)	V1_ignore	6.83	3.05	3.05	3.78	0.25	0.00	2.46	0.97	0.75	0.89
disease	benefit_harm	W5	CCW, A vs B1 (reference)	V2_cluster	6.83	3.05	3.05	3.78	0.25	0.00	2.46	0.97	0.74	0.89
disease	benefit_harm	W5	CCW, A vs B1 (reference)	V3_random	6.85	3.05	3.05	3.80	0.25	0.00	2.54	0.96	0.77	0.88
disease	benefit_harm	W5	CCW, A vs B1 (reference)	V4_within	6.88	3.05	3.05	3.83	0.30	0.00	3.03	0.96	0.82	0.71
disease	benefit_harm	WR	Naive ‘ever early PVI’	V1_ignore	22.13	20.66	7.74	1.47	1.12	12.92	1.93	0.76	0.76	1.00
disease	benefit_harm	WR	Naive ‘ever early PVI’	V2_cluster	22.13	20.66	7.74	1.47	1.12	12.92	1.93	1.11	0.92	1.00
disease	benefit_harm	WR	Naive ‘ever early PVI’	V3_random	19.89	20.66	7.74	-0.77	1.06	12.92	1.91	1.08	0.96	1.00
disease	benefit_harm	WR	Naive ‘ever early PVI’	V4_within	17.98	20.66	7.74	-2.68	1.08	12.92	2.18	1.04	0.75	1.00
disease	benefit_harm	WR	Landmark at 6 months	V1_ignore	22.24	11.10	7.74	11.14	1.05	3.36	1.93	0.79	0.00	1.00
disease	benefit_harm	WR	Landmark at 6 months	V2_cluster	22.24	11.10	7.74	11.14	1.05	3.36	1.93	1.12	0.00	1.00
disease	benefit_harm	WR	Landmark at 6 months	V3_random	19.13	11.10	7.74	8.03	1.03	3.36	1.95	1.06	0.00	1.00
disease	benefit_harm	WR	Landmark at 6 months	V4_within	18.42	11.10	7.74	7.32	1.03	3.36	2.23	1.05	0.03	1.00
disease	benefit_harm	WR	Sequential trials, ITT	V1_ignore	20.35	8.93	7.74	11.41	0.20	1.19	1.99	0.74	0.00	1.00
disease	benefit_harm	WR	Sequential trials, ITT	V2_cluster	20.35	8.93	7.74	11.41	0.20	1.19	1.99	1.08	0.00	1.00
disease	benefit_harm	WR	Sequential trials, ITT	V3_random	17.09	8.93	7.74	8.16	0.20	1.19	1.99	1.01	0.00	1.00
disease	benefit_harm	WR	Sequential trials, ITT	V4_within	16.17	8.93	7.74	7.23	0.22	1.19	2.23	0.99	0.07	1.00
disease	benefit_harm	WR	CCW, A vs B2	V1_ignore	17.14	7.84	7.74	9.30	0.43	0.10	4.27	0.79	0.24	1.00
disease	benefit_harm	WR	CCW, A vs B2	V2_cluster	17.14	7.84	7.74	9.30	0.43	0.10	4.27	0.85	0.27	1.00
disease	benefit_harm	WR	CCW, A vs B2	V3_random	14.96	7.84	7.74	7.12	0.46	0.10	4.56	0.88	0.64	1.00
disease	benefit_harm	WR	CCW, A vs B2	V4_within	14.66	7.84	7.74	6.82	0.50	0.10	5.00	0.90	0.71	0.95
disease	benefit_harm	WR	CCW, A vs B1 (reference)	V1_ignore	17.04	7.74	7.74	9.30	0.43	0.00	4.27	0.79	0.23	1.00
disease	benefit_harm	WR	CCW, A vs B1 (reference)	V2_cluster	17.04	7.74	7.74	9.30	0.43	0.00	4.27	0.85	0.28	1.00
disease	benefit_harm	WR	CCW, A vs B1 (reference)	V3_random	14.83	7.74	7.74	7.09	0.46	0.00	4.56	0.88	0.62	1.00
disease	benefit_harm	WR	CCW, A vs B1 (reference)	V4_within	14.44	7.74	7.74	6.70	0.50	0.00	5.00	0.90	0.72	0.95
disease	harm	W0	Naive ‘ever early PVI’	V1_ignore	6.89	7.18	5.11	-0.29	0.06	2.07	1.65	0.85	0.88	1.00
disease	harm	W0	Naive ‘ever early PVI’	V2_cluster	6.89	7.18	5.11	-0.29	0.06	2.07	1.65	0.85	0.88	1.00
disease	harm	W0	Naive ‘ever early PVI’	V3_random	7.02	7.18	5.11	-0.16	0.06	2.07	1.69	0.85	0.89	1.00
disease	harm	W0	Naive ‘ever early PVI’	V4_within	6.28	7.18	5.11	-0.90	0.12	2.07	2.03	0.87	0.80	0.98
disease	harm	W0	Landmark at 6 months	V1_ignore	7.85	7.95	5.11	-0.10	0.16	2.84	3.61	0.92	0.92	0.81
disease	harm	W0	Landmark at 6 months	V2_cluster	7.85	7.95	5.11	-0.10	0.16	2.84	3.61	0.92	0.92	0.80
disease	harm	W0	Landmark at 6 months	V3_random	7.80	7.95	5.11	-0.15	0.15	2.84	3.62	0.91	0.91	0.78
disease	harm	W0	Landmark at 6 months	V4_within	7.29	7.95	5.11	-0.66	0.29	2.84	4.59	0.88	0.87	0.50
disease	harm	W0	Sequential trials, ITT	V1_ignore	5.70	5.71	5.11	-0.01	0.15	0.61	1.46	0.86	0.91	0.99
disease	harm	W0	Sequential trials, ITT	V2_cluster	5.70	5.71	5.11	-0.01	0.15	0.61	1.46	0.86	0.91	0.99
disease	harm	W0	Sequential trials, ITT	V3_random	5.68	5.71	5.11	-0.03	0.16	0.61	1.55	0.83	0.91	0.99
disease	harm	W0	Sequential trials, ITT	V4_within	5.43	5.71	5.11	-0.29	0.19	0.61	1.86	0.83	0.89	0.94
disease	harm	W0	CCW, A vs B2	V1_ignore	5.32	5.15	5.11	0.17	0.28	0.05	2.81	1.03	0.96	0.44
disease	harm	W0	CCW, A vs B2	V2_cluster	5.32	5.15	5.11	0.17	0.28	0.05	2.81	1.03	0.96	0.46
disease	harm	W0	CCW, A vs B2	V3_random	5.38	5.15	5.11	0.23	0.29	0.05	2.91	1.02	0.97	0.43
disease	harm	W0	CCW, A vs B2	V4_within	5.29	5.15	5.11	0.13	0.36	0.05	3.61	0.96	0.93	0.32
disease	harm	W0	CCW, A vs B1 (reference)	V1_ignore	5.28	5.11	5.11	0.17	0.28	0.00	2.82	1.03	0.96	0.44
disease	harm	W0	CCW, A vs B1 (reference)	V2_cluster	5.28	5.11	5.11	0.17	0.28	0.00	2.82	1.03	0.96	0.46
disease	harm	W0	CCW, A vs B1 (reference)	V3_random	5.34	5.11	5.11	0.23	0.29	0.00	2.91	1.02	0.97	0.43
disease	harm	W0	CCW, A vs B1 (reference)	V4_within	5.24	5.11	5.11	0.13	0.36	0.00	3.61	0.96	0.93	0.32
disease	harm	W1	Naive ‘ever early PVI’	V1_ignore	10.33	9.80	7.18	0.52	0.10	2.62	1.51	1.02	0.95	1.00
disease	harm	W1	Naive ‘ever early PVI’	V2_cluster	10.33	9.80	7.18	0.52	0.10	2.62	1.51	1.06	0.96	1.00
disease	harm	W1	Naive ‘ever early PVI’	V3_random	10.19	9.80	7.18	0.39	0.08	2.62	1.54	1.04	0.97	1.00
disease	harm	W1	Naive ‘ever early PVI’	V4_within	9.11	9.80	7.18	-0.70	0.14	2.62	2.13	0.90	0.85	1.00
disease	harm	W1	Landmark at 6 months	V1_ignore	23.70	19.85	7.18	3.85	0.38	12.67	12.66	0.55	0.84	0.96
disease	harm	W1	Landmark at 6 months	V2_cluster	23.70	19.85	7.18	3.85	0.38	12.67	12.66	0.58	0.84	0.96
disease	harm	W1	Landmark at 6 months	V3_random	22.54	19.85	7.18	2.69	0.32	12.67	12.59	0.56	0.83	0.96
disease	harm	W1	Landmark at 6 months	V4_within	21.36	19.85	7.18	1.51	0.53	12.67	13.13	0.58	0.83	0.94
disease	harm	W1	Sequential trials, ITT	V1_ignore	9.17	7.98	7.18	1.19	0.15	0.80	1.47	0.96	0.91	1.00
disease	harm	W1	Sequential trials, ITT	V2_cluster	9.17	7.98	7.18	1.19	0.15	0.80	1.47	1.01	0.92	1.00
disease	harm	W1	Sequential trials, ITT	V3_random	8.89	7.98	7.18	0.92	0.15	0.80	1.48	1.00	0.95	1.00
disease	harm	W1	Sequential trials, ITT	V4_within	8.20	7.98	7.18	0.22	0.20	0.80	1.95	0.88	0.89	1.00
disease	harm	W1	CCW, A vs B2	V1_ignore	8.36	7.26	7.18	1.11	0.28	0.07	2.85	1.07	0.96	0.85
disease	harm	W1	CCW, A vs B2	V2_cluster	8.36	7.26	7.18	1.11	0.28	0.07	2.85	1.07	0.96	0.85
disease	harm	W1	CCW, A vs B2	V3_random	8.15	7.26	7.18	0.89	0.30	0.07	2.95	1.04	0.96	0.81
disease	harm	W1	CCW, A vs B2	V4_within	7.61	7.26	7.18	0.35	0.36	0.07	3.58	0.97	0.94	0.67
disease	harm	W1	CCW, A vs B1 (reference)	V1_ignore	8.29	7.18	7.18	1.11	0.28	0.00	2.85	1.07	0.96	0.85
disease	harm	W1	CCW, A vs B1 (reference)	V2_cluster	8.29	7.18	7.18	1.11	0.28	0.00	2.85	1.07	0.96	0.85
disease	harm	W1	CCW, A vs B1 (reference)	V3_random	8.08	7.18	7.18	0.90	0.30	0.00	2.95	1.04	0.96	0.81
disease	harm	W1	CCW, A vs B1 (reference)	V4_within	7.53	7.18	7.18	0.34	0.36	0.00	3.57	0.97	0.94	0.66
disease	harm	W1_rho0	Naive ‘ever early PVI’	V1_ignore	9.20	9.50	7.12	-0.31	0.08	2.38	1.41	1.07	0.95	1.00
disease	harm	W1_rho0	Naive ‘ever early PVI’	V2_cluster	9.20	9.50	7.12	-0.31	0.08	2.38	1.41	1.09	0.96	1.00
disease	harm	W1_rho0	Naive ‘ever early PVI’	V3_random	9.35	9.50	7.12	-0.16	0.07	2.38	1.45	1.08	0.97	1.00
disease	harm	W1_rho0	Naive ‘ever early PVI’	V4_within	8.70	9.50	7.12	-0.81	0.13	2.38	1.84	1.04	0.92	1.00
disease	harm	W1_rho0	Landmark at 6 months	V1_ignore	21.20	20.08	7.12	1.12	0.35	12.96	11.58	0.62	0.80	0.95
disease	harm	W1_rho0	Landmark at 6 months	V2_cluster	21.20	20.08	7.12	1.12	0.35	12.96	11.58	0.64	0.78	0.96
disease	harm	W1_rho0	Landmark at 6 months	V3_random	20.83	20.08	7.12	0.75	0.28	12.96	11.51	0.63	0.75	0.94
disease	harm	W1_rho0	Landmark at 6 months	V4_within	20.85	20.08	7.12	0.77	0.52	12.96	13.19	0.62	0.72	0.86
disease	harm	W1_rho0	Sequential trials, ITT	V1_ignore	8.03	7.97	7.12	0.06	0.13	0.84	1.25	1.09	0.97	1.00
disease	harm	W1_rho0	Sequential trials, ITT	V2_cluster	8.03	7.97	7.12	0.06	0.13	0.84	1.25	1.12	0.98	1.00
disease	harm	W1_rho0	Sequential trials, ITT	V3_random	8.04	7.97	7.12	0.07	0.13	0.84	1.30	1.10	0.98	1.00
disease	harm	W1_rho0	Sequential trials, ITT	V4_within	7.83	7.97	7.12	-0.14	0.18	0.84	1.75	0.98	0.96	1.00
disease	harm	W1_rho0	CCW, A vs B2	V1_ignore	7.42	7.19	7.12	0.23	0.30	0.06	2.96	1.03	0.92	0.78
disease	harm	W1_rho0	CCW, A vs B2	V2_cluster	7.42	7.19	7.12	0.23	0.30	0.06	2.96	1.03	0.92	0.77
disease	harm	W1_rho0	CCW, A vs B2	V3_random	7.55	7.19	7.12	0.36	0.31	0.06	3.10	1.02	0.90	0.75
disease	harm	W1_rho0	CCW, A vs B2	V4_within	7.43	7.19	7.12	0.25	0.38	0.06	3.77	0.97	0.90	0.61
disease	harm	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	7.36	7.12	7.12	0.23	0.30	0.00	2.97	1.03	0.92	0.77
disease	harm	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	7.36	7.12	7.12	0.23	0.30	0.00	2.97	1.03	0.92	0.76
disease	harm	W1_rho0	CCW, A vs B1 (reference)	V3_random	7.49	7.12	7.12	0.37	0.31	0.00	3.10	1.01	0.91	0.75
disease	harm	W1_rho0	CCW, A vs B1 (reference)	V4_within	7.37	7.12	7.12	0.24	0.38	0.00	3.78	0.97	0.90	0.60
disease	harm	W2	Naive ‘ever early PVI’	V1_ignore	7.23	17.68	5.09	-10.45	1.00	12.59	1.51	0.97	0.00	1.00
disease	harm	W2	Naive ‘ever early PVI’	V2_cluster	7.23	17.68	5.09	-10.45	1.00	12.59	1.51	0.98	0.00	1.00
disease	harm	W2	Naive ‘ever early PVI’	V3_random	8.71	17.68	5.09	-8.97	0.94	12.59	2.64	0.96	0.13	0.99
disease	harm	W2	Naive ‘ever early PVI’	V4_within	6.22	17.68	5.09	-11.46	1.03	12.59	2.81	0.89	0.06	0.78
disease	harm	W2	Landmark at 6 months	V1_ignore	8.27	8.20	5.09	0.07	0.79	3.11	4.25	0.92	0.91	0.76
disease	harm	W2	Landmark at 6 months	V2_cluster	8.27	8.20	5.09	0.07	0.79	3.11	4.25	0.91	0.90	0.79
disease	harm	W2	Landmark at 6 months	V3_random	7.95	8.20	5.09	-0.25	0.70	3.11	5.01	0.86	0.88	0.52
disease	harm	W2	Landmark at 6 months	V4_within	7.12	8.20	5.09	-1.08	0.70	3.11	5.84	0.82	0.82	0.30
disease	harm	W2	Sequential trials, ITT	V1_ignore	5.91	5.72	5.09	0.19	0.14	0.63	1.40	0.92	0.92	1.00
disease	harm	W2	Sequential trials, ITT	V2_cluster	5.91	5.72	5.09	0.19	0.14	0.63	1.40	0.93	0.95	1.00
disease	harm	W2	Sequential trials, ITT	V3_random	5.72	5.72	5.09	0.00	0.20	0.63	2.02	0.87	0.86	0.93
disease	harm	W2	Sequential trials, ITT	V4_within	5.43	5.72	5.09	-0.29	0.23	0.63	2.29	0.85	0.85	0.84
disease	harm	W2	CCW, A vs B2	V1_ignore	5.28	5.15	5.09	0.13	0.31	0.06	3.10	0.98	0.90	0.36
disease	harm	W2	CCW, A vs B2	V2_cluster	5.28	5.15	5.09	0.13	0.31	0.06	3.10	0.97	0.91	0.39
disease	harm	W2	CCW, A vs B2	V3_random	5.23	5.15	5.09	0.08	0.40	0.06	3.97	0.96	0.93	0.20
disease	harm	W2	CCW, A vs B2	V4_within	5.03	5.15	5.09	-0.12	0.48	0.06	4.83	0.87	0.91	0.19
disease	harm	W2	CCW, A vs B1 (reference)	V1_ignore	5.24	5.09	5.09	0.15	0.31	0.00	3.10	0.98	0.90	0.35
disease	harm	W2	CCW, A vs B1 (reference)	V2_cluster	5.24	5.09	5.09	0.15	0.31	0.00	3.10	0.97	0.91	0.38
disease	harm	W2	CCW, A vs B1 (reference)	V3_random	5.18	5.09	5.09	0.09	0.40	0.00	3.98	0.96	0.93	0.20
disease	harm	W2	CCW, A vs B1 (reference)	V4_within	4.94	5.09	5.09	-0.15	0.48	0.00	4.84	0.87	0.91	0.16
disease	harm	W3	Naive ‘ever early PVI’	V1_ignore	8.16	14.58	4.97	-6.42	0.94	9.62	1.39	1.08	0.02	1.00
disease	harm	W3	Naive ‘ever early PVI’	V2_cluster	8.16	14.58	4.97	-6.42	0.94	9.62	1.39	1.08	0.02	1.00
disease	harm	W3	Naive ‘ever early PVI’	V3_random	8.48	14.58	4.97	-6.10	0.87	9.62	2.34	1.05	0.25	1.00
disease	harm	W3	Naive ‘ever early PVI’	V4_within	5.66	14.58	4.97	-8.93	0.95	9.62	2.37	0.98	0.13	0.72
disease	harm	W3	Landmark at 6 months	V1_ignore	8.43	6.90	4.97	1.52	0.67	1.94	3.39	1.00	0.96	0.87
disease	harm	W3	Landmark at 6 months	V2_cluster	8.43	6.90	4.97	1.52	0.67	1.94	3.39	0.98	0.95	0.87
disease	harm	W3	Landmark at 6 months	V3_random	7.17	6.90	4.97	0.27	0.54	1.94	3.81	0.92	0.94	0.58
disease	harm	W3	Landmark at 6 months	V4_within	5.95	6.90	4.97	-0.95	0.56	1.94	4.36	0.92	0.87	0.34
disease	harm	W3	Sequential trials, ITT	V1_ignore	6.94	5.58	4.97	1.36	0.13	0.62	1.29	1.05	0.93	1.00
disease	harm	W3	Sequential trials, ITT	V2_cluster	6.94	5.58	4.97	1.36	0.13	0.62	1.29	1.05	0.90	1.00
disease	harm	W3	Sequential trials, ITT	V3_random	5.77	5.58	4.97	0.19	0.17	0.62	1.65	1.04	0.96	0.99
disease	harm	W3	Sequential trials, ITT	V4_within	5.07	5.58	4.97	-0.51	0.20	0.62	1.99	0.97	0.90	0.82
disease	harm	W3	CCW, A vs B2	V1_ignore	5.71	5.02	4.97	0.70	0.28	0.05	2.84	1.07	0.96	0.49
disease	harm	W3	CCW, A vs B2	V2_cluster	5.71	5.02	4.97	0.70	0.28	0.05	2.84	1.08	0.96	0.47
disease	harm	W3	CCW, A vs B2	V3_random	5.14	5.02	4.97	0.12	0.38	0.05	3.75	0.97	0.93	0.19
disease	harm	W3	CCW, A vs B2	V4_within	4.73	5.02	4.97	-0.29	0.44	0.05	4.42	0.92	0.90	0.15
disease	harm	W3	CCW, A vs B1 (reference)	V1_ignore	5.66	4.97	4.97	0.69	0.28	0.00	2.84	1.07	0.96	0.49
disease	harm	W3	CCW, A vs B1 (reference)	V2_cluster	5.66	4.97	4.97	0.69	0.28	0.00	2.84	1.08	0.96	0.46
disease	harm	W3	CCW, A vs B1 (reference)	V3_random	5.09	4.97	4.97	0.12	0.38	0.00	3.75	0.97	0.93	0.19
disease	harm	W3	CCW, A vs B1 (reference)	V4_within	4.65	4.97	4.97	-0.32	0.44	0.00	4.42	0.92	0.91	0.14
disease	harm	W4	Naive ‘ever early PVI’	V1_ignore	6.51	6.73	4.80	-0.23	0.07	1.93	1.37	1.03	0.93	1.00
disease	harm	W4	Naive ‘ever early PVI’	V2_cluster	6.51	6.73	4.80	-0.23	0.07	1.93	1.37	1.02	0.93	1.00
disease	harm	W4	Naive ‘ever early PVI’	V3_random	6.62	6.73	4.80	-0.12	0.07	1.93	1.46	0.99	0.95	1.00
disease	harm	W4	Naive ‘ever early PVI’	V4_within	5.70	6.73	4.80	-1.03	0.11	1.93	1.60	1.09	0.88	0.97
disease	harm	W4	Landmark at 6 months	V1_ignore	7.18	7.23	4.80	-0.05	0.16	2.43	3.08	1.04	0.93	0.70
disease	harm	W4	Landmark at 6 months	V2_cluster	7.18	7.23	4.80	-0.05	0.16	2.43	3.08	1.04	0.93	0.71
disease	harm	W4	Landmark at 6 months	V3_random	7.25	7.23	4.80	0.01	0.14	2.43	3.34	1.00	0.95	0.71
disease	harm	W4	Landmark at 6 months	V4_within	6.84	7.23	4.80	-0.39	0.34	2.43	5.38	0.83	0.90	0.35
disease	harm	W4	Sequential trials, ITT	V1_ignore	5.32	5.42	4.80	-0.10	0.12	0.62	1.24	1.01	0.93	1.00
disease	harm	W4	Sequential trials, ITT	V2_cluster	5.32	5.42	4.80	-0.10	0.12	0.62	1.24	1.01	0.92	1.00
disease	harm	W4	Sequential trials, ITT	V3_random	5.26	5.42	4.80	-0.16	0.13	0.62	1.30	0.99	0.92	1.00
disease	harm	W4	Sequential trials, ITT	V4_within	4.88	5.42	4.80	-0.54	0.14	0.62	1.44	1.05	0.92	0.96
disease	harm	W4	CCW, A vs B2	V1_ignore	5.11	5.16	4.80	-0.05	0.27	0.36	2.71	1.04	0.94	0.40
disease	harm	W4	CCW, A vs B2	V2_cluster	5.11	5.16	4.80	-0.05	0.27	0.36	2.71	1.03	0.94	0.42
disease	harm	W4	CCW, A vs B2	V3_random	5.22	5.16	4.80	0.05	0.28	0.36	2.80	1.02	0.95	0.42
disease	harm	W4	CCW, A vs B2	V4_within	5.15	5.16	4.80	-0.02	0.34	0.36	3.37	1.00	0.90	0.29
disease	harm	W4	CCW, A vs B1 (reference)	V1_ignore	4.79	4.80	4.80	-0.01	0.27	0.00	2.70	1.04	0.94	0.38
disease	harm	W4	CCW, A vs B1 (reference)	V2_cluster	4.79	4.80	4.80	-0.01	0.27	0.00	2.70	1.03	0.94	0.37
disease	harm	W4	CCW, A vs B1 (reference)	V3_random	4.84	4.80	4.80	0.04	0.28	0.00	2.80	1.02	0.95	0.35
disease	harm	W4	CCW, A vs B1 (reference)	V4_within	4.75	4.80	4.80	-0.05	0.34	0.00	3.38	1.00	0.90	0.25
disease	harm	W5	Naive ‘ever early PVI’	V1_ignore	12.74	7.23	5.11	5.51	0.11	2.13	1.09	1.08	0.00	1.00
disease	harm	W5	Naive ‘ever early PVI’	V2_cluster	12.74	7.23	5.11	5.51	0.11	2.13	1.09	1.08	0.00	1.00
disease	harm	W5	Naive ‘ever early PVI’	V3_random	12.83	7.23	5.11	5.60	0.11	2.13	1.10	1.09	0.00	1.00
disease	harm	W5	Naive ‘ever early PVI’	V4_within	12.55	7.23	5.11	5.32	0.12	2.13	1.28	1.12	0.01	1.00
disease	harm	W5	Landmark at 6 months	V1_ignore	10.68	8.16	5.11	2.52	0.36	3.06	1.11	1.08	0.43	1.00
disease	harm	W5	Landmark at 6 months	V2_cluster	10.68	8.16	5.11	2.52	0.36	3.06	1.11	1.07	0.41	1.00
disease	harm	W5	Landmark at 6 months	V3_random	10.72	8.16	5.11	2.55	0.36	3.06	1.11	1.10	0.44	1.00
disease	harm	W5	Landmark at 6 months	V4_within	10.65	8.16	5.11	2.48	0.37	3.06	1.30	1.13	0.66	1.00
disease	harm	W5	Sequential trials, ITT	V1_ignore	10.66	5.71	5.11	4.94	0.11	0.61	1.09	1.08	0.00	1.00
disease	harm	W5	Sequential trials, ITT	V2_cluster	10.66	5.71	5.11	4.94	0.11	0.61	1.09	1.07	0.00	1.00
disease	harm	W5	Sequential trials, ITT	V3_random	10.68	5.71	5.11	4.96	0.11	0.61	1.08	1.11	0.00	1.00
disease	harm	W5	Sequential trials, ITT	V4_within	10.63	5.71	5.11	4.92	0.12	0.61	1.22	1.17	0.04	1.00
disease	harm	W5	CCW, A vs B2	V1_ignore	9.58	5.15	5.11	4.42	0.25	0.05	2.49	1.05	0.60	0.99
disease	harm	W5	CCW, A vs B2	V2_cluster	9.58	5.15	5.11	4.42	0.25	0.05	2.49	1.05	0.60	0.98
disease	harm	W5	CCW, A vs B2	V3_random	9.55	5.15	5.11	4.40	0.26	0.05	2.58	1.02	0.61	0.99
disease	harm	W5	CCW, A vs B2	V4_within	9.58	5.15	5.11	4.43	0.30	0.05	3.05	1.00	0.68	0.96
disease	harm	W5	CCW, A vs B1 (reference)	V1_ignore	9.54	5.11	5.11	4.43	0.25	0.00	2.49	1.05	0.61	0.98
disease	harm	W5	CCW, A vs B1 (reference)	V2_cluster	9.54	5.11	5.11	4.43	0.25	0.00	2.49	1.05	0.61	0.98
disease	harm	W5	CCW, A vs B1 (reference)	V3_random	9.51	5.11	5.11	4.41	0.26	0.00	2.58	1.02	0.61	0.99
disease	harm	W5	CCW, A vs B1 (reference)	V4_within	9.54	5.11	5.11	4.43	0.31	0.00	3.05	1.00	0.68	0.96
disease	harm	WR	Naive ‘ever early PVI’	V1_ignore	18.78	17.32	6.93	1.46	0.98	10.39	1.62	0.88	0.81	1.00
disease	harm	WR	Naive ‘ever early PVI’	V2_cluster	18.78	17.32	6.93	1.46	0.98	10.39	1.62	1.08	0.90	1.00
disease	harm	WR	Naive ‘ever early PVI’	V3_random	17.88	17.32	6.93	0.56	0.97	10.39	2.05	0.94	0.93	1.00
disease	harm	WR	Naive ‘ever early PVI’	V4_within	16.28	17.32	6.93	-1.04	1.00	10.39	2.33	0.92	0.84	1.00
disease	harm	WR	Landmark at 6 months	V1_ignore	16.73	15.52	6.93	1.21	1.07	8.59	1.66	0.88	0.83	1.00
disease	harm	WR	Landmark at 6 months	V2_cluster	16.73	15.52	6.93	1.21	1.07	8.59	1.66	1.07	0.93	1.00
disease	harm	WR	Landmark at 6 months	V3_random	15.00	15.52	6.93	-0.52	1.07	8.59	1.97	0.98	0.95	1.00
disease	harm	WR	Landmark at 6 months	V4_within	14.26	15.52	6.93	-1.26	1.08	8.59	2.31	0.97	0.86	1.00
disease	harm	WR	Sequential trials, ITT	V1_ignore	16.93	7.68	6.93	9.25	0.16	0.75	1.58	0.91	0.00	1.00
disease	harm	WR	Sequential trials, ITT	V2_cluster	16.93	7.68	6.93	9.25	0.16	0.75	1.58	1.11	0.00	1.00
disease	harm	WR	Sequential trials, ITT	V3_random	15.11	7.68	6.93	7.43	0.20	0.75	2.00	0.93	0.00	1.00
disease	harm	WR	Sequential trials, ITT	V4_within	14.35	7.68	6.93	6.67	0.23	0.75	2.35	0.88	0.12	1.00
disease	harm	WR	CCW, A vs B2	V1_ignore	14.14	7.08	6.93	7.06	0.39	0.15	3.88	0.84	0.48	1.00
disease	harm	WR	CCW, A vs B2	V2_cluster	14.14	7.08	6.93	7.06	0.39	0.15	3.88	0.87	0.50	1.00
disease	harm	WR	CCW, A vs B2	V3_random	13.49	7.08	6.93	6.41	0.39	0.15	3.94	1.01	0.73	1.00
disease	harm	WR	CCW, A vs B2	V4_within	13.31	7.08	6.93	6.24	0.43	0.15	4.34	1.04	0.79	0.94
disease	harm	WR	CCW, A vs B1 (reference)	V1_ignore	13.99	6.93	6.93	7.06	0.39	0.00	3.87	0.85	0.48	1.00
disease	harm	WR	CCW, A vs B1 (reference)	V2_cluster	13.99	6.93	6.93	7.06	0.39	0.00	3.87	0.87	0.50	1.00
disease	harm	WR	CCW, A vs B1 (reference)	V3_random	13.31	6.93	6.93	6.38	0.39	0.00	3.94	1.01	0.73	1.00
disease	harm	WR	CCW, A vs B1 (reference)	V4_within	13.00	6.93	6.93	6.07	0.43	0.00	4.34	1.04	0.80	0.93
disease	null	W0	Naive ‘ever early PVI’	V1_ignore	1.06	1.25	0.00	-0.20	0.06	1.25	1.15	1.03	0.94	0.07
disease	null	W0	Naive ‘ever early PVI’	V2_cluster	1.06	1.25	0.00	-0.20	0.06	1.25	1.15	1.02	0.95	0.07
disease	null	W0	Naive ‘ever early PVI’	V3_random	1.16	1.25	0.00	-0.10	0.06	1.25	1.19	1.03	0.92	0.13
disease	null	W0	Naive ‘ever early PVI’	V4_within	0.54	1.25	0.00	-0.71	0.10	1.25	1.45	0.98	0.84	0.03
disease	null	W0	Landmark at 6 months	V1_ignore	-0.16	-0.30	0.00	0.14	0.06	-0.30	0.99	1.06	0.97	0.06
disease	null	W0	Landmark at 6 months	V2_cluster	-0.16	-0.30	0.00	0.14	0.06	-0.30	0.99	1.06	0.97	0.06
disease	null	W0	Landmark at 6 months	V3_random	-0.12	-0.30	0.00	0.18	0.05	-0.30	1.02	1.05	0.97	0.06
disease	null	W0	Landmark at 6 months	V4_within	-0.33	-0.30	0.00	-0.04	0.07	-0.30	1.26	1.01	0.94	0.08
disease	null	W0	Sequential trials, ITT	V1_ignore	-0.02	0.00	0.00	-0.02	0.10	0.00	0.96	1.06	0.95	0.05
disease	null	W0	Sequential trials, ITT	V2_cluster	-0.02	0.00	0.00	-0.02	0.10	0.00	0.96	1.06	0.94	0.06
disease	null	W0	Sequential trials, ITT	V3_random	-0.03	0.00	0.00	-0.03	0.10	0.00	0.98	1.06	0.95	0.05
disease	null	W0	Sequential trials, ITT	V4_within	-0.12	0.00	0.00	-0.12	0.12	0.00	1.19	1.03	0.91	0.09
disease	null	W0	CCW, A vs B2	V1_ignore	-0.33	0.00	0.00	-0.33	0.26	0.00	2.56	0.86	0.85	0.15
disease	null	W0	CCW, A vs B2	V2_cluster	-0.33	0.00	0.00	-0.33	0.26	0.00	2.56	0.86	0.85	0.15
disease	null	W0	CCW, A vs B2	V3_random	-0.21	0.00	0.00	-0.21	0.27	0.00	2.69	0.86	0.86	0.14
disease	null	W0	CCW, A vs B2	V4_within	-0.14	0.00	0.00	-0.14	0.31	0.00	3.11	0.89	0.89	0.11
disease	null	W0	CCW, A vs B1 (reference)	V1_ignore	-0.33	0.00	0.00	-0.33	0.26	0.00	2.56	0.86	0.86	0.14
disease	null	W0	CCW, A vs B1 (reference)	V2_cluster	-0.33	0.00	0.00	-0.33	0.26	0.00	2.56	0.86	0.85	0.15
disease	null	W0	CCW, A vs B1 (reference)	V3_random	-0.21	0.00	0.00	-0.21	0.27	0.00	2.69	0.86	0.86	0.14
disease	null	W0	CCW, A vs B1 (reference)	V4_within	-0.14	0.00	0.00	-0.14	0.31	0.00	3.11	0.89	0.89	0.11
disease	null	W1	Naive ‘ever early PVI’	V1_ignore	1.13	1.40	0.00	-0.27	0.07	1.40	1.37	0.92	0.89	0.10
disease	null	W1	Naive ‘ever early PVI’	V2_cluster	1.13	1.40	0.00	-0.27	0.07	1.40	1.37	0.92	0.88	0.11
disease	null	W1	Naive ‘ever early PVI’	V3_random	1.28	1.40	0.00	-0.12	0.06	1.40	1.42	0.92	0.93	0.12
disease	null	W1	Naive ‘ever early PVI’	V4_within	0.69	1.40	0.00	-0.71	0.12	1.40	1.66	0.95	0.85	0.09
disease	null	W1	Landmark at 6 months	V1_ignore	-0.17	-0.28	0.00	0.11	0.05	-0.28	0.99	1.10	0.98	0.05
disease	null	W1	Landmark at 6 months	V2_cluster	-0.17	-0.28	0.00	0.11	0.05	-0.28	0.99	1.09	0.97	0.05
disease	null	W1	Landmark at 6 months	V3_random	-0.12	-0.28	0.00	0.16	0.05	-0.28	1.03	1.06	0.97	0.04
disease	null	W1	Landmark at 6 months	V4_within	-0.22	-0.28	0.00	0.06	0.09	-0.28	1.35	1.04	0.92	0.11
disease	null	W1	Sequential trials, ITT	V1_ignore	-0.11	0.00	0.00	-0.11	0.10	0.00	0.96	1.07	0.94	0.06
disease	null	W1	Sequential trials, ITT	V2_cluster	-0.11	0.00	0.00	-0.11	0.10	0.00	0.96	1.07	0.94	0.06
disease	null	W1	Sequential trials, ITT	V3_random	-0.11	0.00	0.00	-0.11	0.10	0.00	0.99	1.05	0.94	0.06
disease	null	W1	Sequential trials, ITT	V4_within	-0.12	0.00	0.00	-0.12	0.13	0.00	1.26	1.02	0.92	0.08
disease	null	W1	CCW, A vs B2	V1_ignore	-0.01	0.00	0.00	-0.01	0.25	0.00	2.51	0.95	0.88	0.12
disease	null	W1	CCW, A vs B2	V2_cluster	-0.01	0.00	0.00	-0.01	0.25	0.00	2.51	0.95	0.88	0.12
disease	null	W1	CCW, A vs B2	V3_random	0.02	0.00	0.00	0.02	0.27	0.00	2.67	0.91	0.88	0.12
disease	null	W1	CCW, A vs B2	V4_within	0.22	0.00	0.00	0.22	0.36	0.00	3.61	0.84	0.84	0.16
disease	null	W1	CCW, A vs B1 (reference)	V1_ignore	-0.01	0.00	0.00	-0.01	0.25	0.00	2.51	0.95	0.88	0.12
disease	null	W1	CCW, A vs B1 (reference)	V2_cluster	-0.01	0.00	0.00	-0.01	0.25	0.00	2.51	0.95	0.88	0.12
disease	null	W1	CCW, A vs B1 (reference)	V3_random	0.02	0.00	0.00	0.02	0.27	0.00	2.67	0.91	0.88	0.12
disease	null	W1	CCW, A vs B1 (reference)	V4_within	0.21	0.00	0.00	0.21	0.36	0.00	3.61	0.84	0.85	0.15
disease	null	W1_rho0	Naive ‘ever early PVI’	V1_ignore	0.95	1.11	0.00	-0.16	0.06	1.11	1.19	1.01	0.91	0.12
disease	null	W1_rho0	Naive ‘ever early PVI’	V2_cluster	0.95	1.11	0.00	-0.16	0.06	1.11	1.19	1.00	0.91	0.12
disease	null	W1_rho0	Naive ‘ever early PVI’	V3_random	1.07	1.11	0.00	-0.04	0.06	1.11	1.28	0.97	0.92	0.14
disease	null	W1_rho0	Naive ‘ever early PVI’	V4_within	0.46	1.11	0.00	-0.65	0.11	1.11	1.43	1.01	0.89	0.08
disease	null	W1_rho0	Landmark at 6 months	V1_ignore	-0.31	-0.46	0.00	0.15	0.05	-0.46	0.98	1.06	0.95	0.11
disease	null	W1_rho0	Landmark at 6 months	V2_cluster	-0.31	-0.46	0.00	0.15	0.05	-0.46	0.98	1.05	0.94	0.11
disease	null	W1_rho0	Landmark at 6 months	V3_random	-0.29	-0.46	0.00	0.18	0.05	-0.46	1.02	1.03	0.93	0.10
disease	null	W1_rho0	Landmark at 6 months	V4_within	-0.49	-0.46	0.00	-0.02	0.08	-0.46	1.27	1.00	0.90	0.13
disease	null	W1_rho0	Sequential trials, ITT	V1_ignore	-0.16	0.00	0.00	-0.16	0.10	0.00	1.03	0.98	0.91	0.09
disease	null	W1_rho0	Sequential trials, ITT	V2_cluster	-0.16	0.00	0.00	-0.16	0.10	0.00	1.03	0.98	0.91	0.09
disease	null	W1_rho0	Sequential trials, ITT	V3_random	-0.19	0.00	0.00	-0.19	0.11	0.00	1.06	0.97	0.91	0.09
disease	null	W1_rho0	Sequential trials, ITT	V4_within	-0.29	0.00	0.00	-0.29	0.12	0.00	1.23	0.99	0.90	0.10
disease	null	W1_rho0	CCW, A vs B2	V1_ignore	-0.03	0.00	0.00	-0.03	0.25	0.00	2.48	0.91	0.90	0.10
disease	null	W1_rho0	CCW, A vs B2	V2_cluster	-0.03	0.00	0.00	-0.03	0.25	0.00	2.48	0.91	0.88	0.12
disease	null	W1_rho0	CCW, A vs B2	V3_random	-0.10	0.00	0.00	-0.10	0.24	0.00	2.45	0.92	0.90	0.10
disease	null	W1_rho0	CCW, A vs B2	V4_within	-0.27	0.00	0.00	-0.27	0.26	0.00	2.61	0.98	0.88	0.12
disease	null	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	-0.03	0.00	0.00	-0.03	0.25	0.00	2.48	0.91	0.90	0.10
disease	null	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	-0.03	0.00	0.00	-0.03	0.25	0.00	2.48	0.91	0.88	0.12
disease	null	W1_rho0	CCW, A vs B1 (reference)	V3_random	-0.10	0.00	0.00	-0.10	0.24	0.00	2.45	0.92	0.90	0.10
disease	null	W1_rho0	CCW, A vs B1 (reference)	V4_within	-0.27	0.00	0.00	-0.27	0.26	0.00	2.61	0.97	0.88	0.12
disease	null	W2	Naive ‘ever early PVI’	V1_ignore	1.70	12.65	0.00	-10.94	1.12	12.65	1.27	1.04	0.00	0.16
disease	null	W2	Naive ‘ever early PVI’	V2_cluster	1.70	12.65	0.00	-10.94	1.12	12.65	1.27	1.04	0.00	0.14
disease	null	W2	Naive ‘ever early PVI’	V3_random	3.27	12.65	0.00	-9.37	1.10	12.65	2.44	1.07	0.07	0.20
disease	null	W2	Naive ‘ever early PVI’	V4_within	0.82	12.65	0.00	-11.83	1.19	12.65	2.96	0.89	0.02	0.06
disease	null	W2	Landmark at 6 months	V1_ignore	0.32	0.03	0.00	0.29	0.32	0.03	1.08	1.05	0.92	0.08
disease	null	W2	Landmark at 6 months	V2_cluster	0.32	0.03	0.00	0.29	0.32	0.03	1.08	1.05	0.93	0.07
disease	null	W2	Landmark at 6 months	V3_random	0.18	0.03	0.00	0.15	0.29	0.03	1.96	0.96	0.93	0.06
disease	null	W2	Landmark at 6 months	V4_within	-0.18	0.03	0.00	-0.21	0.33	0.03	2.86	0.84	0.91	0.09
disease	null	W2	Sequential trials, ITT	V1_ignore	0.44	0.00	0.00	0.44	0.11	0.00	1.06	1.03	0.92	0.08
disease	null	W2	Sequential trials, ITT	V2_cluster	0.44	0.00	0.00	0.44	0.11	0.00	1.06	1.03	0.93	0.07
disease	null	W2	Sequential trials, ITT	V3_random	0.14	0.00	0.00	0.14	0.16	0.00	1.56	0.94	0.92	0.08
disease	null	W2	Sequential trials, ITT	V4_within	-0.03	0.00	0.00	-0.03	0.19	0.00	1.88	0.84	0.93	0.07
disease	null	W2	CCW, A vs B2	V1_ignore	0.83	0.00	0.00	0.83	0.28	0.00	2.85	0.97	0.95	0.05
disease	null	W2	CCW, A vs B2	V2_cluster	0.83	0.00	0.00	0.83	0.28	0.00	2.85	0.96	0.95	0.05
disease	null	W2	CCW, A vs B2	V3_random	0.96	0.00	0.00	0.96	0.55	0.00	5.45	0.70	0.92	0.08
disease	null	W2	CCW, A vs B2	V4_within	0.78	0.00	0.00	0.78	0.66	0.00	6.64	0.60	0.90	0.10
disease	null	W2	CCW, A vs B1 (reference)	V1_ignore	0.84	0.00	0.00	0.84	0.28	0.00	2.84	0.97	0.95	0.05
disease	null	W2	CCW, A vs B1 (reference)	V2_cluster	0.84	0.00	0.00	0.84	0.28	0.00	2.84	0.96	0.95	0.05
disease	null	W2	CCW, A vs B1 (reference)	V3_random	0.96	0.00	0.00	0.96	0.54	0.00	5.45	0.70	0.92	0.08
disease	null	W2	CCW, A vs B1 (reference)	V4_within	0.79	0.00	0.00	0.79	0.66	0.00	6.63	0.60	0.89	0.11
disease	null	W3	Naive ‘ever early PVI’	V1_ignore	2.63	10.69	0.00	-8.07	0.79	10.69	1.45	0.90	0.00	0.51
disease	null	W3	Naive ‘ever early PVI’	V2_cluster	2.63	10.69	0.00	-8.07	0.79	10.69	1.45	0.89	0.00	0.55
disease	null	W3	Naive ‘ever early PVI’	V3_random	3.19	10.69	0.00	-7.50	0.75	10.69	2.27	0.99	0.10	0.27
disease	null	W3	Naive ‘ever early PVI’	V4_within	0.47	10.69	0.00	-10.22	0.81	10.69	2.16	0.95	0.03	0.08
disease	null	W3	Landmark at 6 months	V1_ignore	1.18	0.13	0.00	1.05	0.36	0.13	1.28	0.90	0.85	0.17
disease	null	W3	Landmark at 6 months	V2_cluster	1.18	0.13	0.00	1.05	0.36	0.13	1.28	0.89	0.85	0.19
disease	null	W3	Landmark at 6 months	V3_random	0.19	0.13	0.00	0.07	0.32	0.13	1.70	0.88	0.92	0.08
disease	null	W3	Landmark at 6 months	V4_within	-0.55	0.13	0.00	-0.68	0.33	0.13	2.00	0.88	0.84	0.15
disease	null	W3	Sequential trials, ITT	V1_ignore	1.34	0.00	0.00	1.34	0.13	0.00	1.25	0.90	0.74	0.26
disease	null	W3	Sequential trials, ITT	V2_cluster	1.34	0.00	0.00	1.34	0.13	0.00	1.25	0.89	0.75	0.25
disease	null	W3	Sequential trials, ITT	V3_random	0.27	0.00	0.00	0.27	0.17	0.00	1.68	0.84	0.87	0.13
disease	null	W3	Sequential trials, ITT	V4_within	-0.19	0.00	0.00	-0.19	0.19	0.00	1.90	0.82	0.84	0.16
disease	null	W3	CCW, A vs B2	V1_ignore	0.88	0.00	0.00	0.88	0.28	0.00	2.77	0.94	0.93	0.07
disease	null	W3	CCW, A vs B2	V2_cluster	0.88	0.00	0.00	0.88	0.28	0.00	2.77	0.95	0.93	0.07
disease	null	W3	CCW, A vs B2	V3_random	0.21	0.00	0.00	0.21	0.34	0.00	3.40	0.91	0.85	0.15
disease	null	W3	CCW, A vs B2	V4_within	-0.26	0.00	0.00	-0.26	0.37	0.00	3.68	0.94	0.81	0.19
disease	null	W3	CCW, A vs B1 (reference)	V1_ignore	0.86	0.00	0.00	0.86	0.28	0.00	2.77	0.94	0.93	0.07
disease	null	W3	CCW, A vs B1 (reference)	V2_cluster	0.86	0.00	0.00	0.86	0.28	0.00	2.77	0.95	0.93	0.07
disease	null	W3	CCW, A vs B1 (reference)	V3_random	0.20	0.00	0.00	0.20	0.34	0.00	3.40	0.91	0.85	0.15
disease	null	W3	CCW, A vs B1 (reference)	V4_within	-0.26	0.00	0.00	-0.26	0.37	0.00	3.67	0.94	0.81	0.19
disease	null	W4	Naive ‘ever early PVI’	V1_ignore	1.09	1.48	0.00	-0.39	0.08	1.48	1.25	0.97	0.90	0.12
disease	null	W4	Naive ‘ever early PVI’	V2_cluster	1.09	1.48	0.00	-0.39	0.08	1.48	1.25	0.97	0.90	0.12
disease	null	W4	Naive ‘ever early PVI’	V3_random	1.19	1.48	0.00	-0.29	0.07	1.48	1.28	0.97	0.91	0.12
disease	null	W4	Naive ‘ever early PVI’	V4_within	0.59	1.48	0.00	-0.89	0.12	1.48	1.49	0.98	0.85	0.03
disease	null	W4	Landmark at 6 months	V1_ignore	-0.02	-0.05	0.00	0.03	0.06	-0.05	1.10	0.99	0.96	0.05
disease	null	W4	Landmark at 6 months	V2_cluster	-0.02	-0.05	0.00	0.03	0.06	-0.05	1.10	0.99	0.96	0.04
disease	null	W4	Landmark at 6 months	V3_random	0.04	-0.05	0.00	0.09	0.05	-0.05	1.12	0.99	0.94	0.06
disease	null	W4	Landmark at 6 months	V4_within	-0.15	-0.05	0.00	-0.10	0.08	-0.05	1.35	1.01	0.92	0.08
disease	null	W4	Sequential trials, ITT	V1_ignore	0.06	0.00	0.00	0.06	0.10	0.00	1.04	1.00	0.96	0.04
disease	null	W4	Sequential trials, ITT	V2_cluster	0.06	0.00	0.00	0.06	0.10	0.00	1.04	1.00	0.96	0.04
disease	null	W4	Sequential trials, ITT	V3_random	0.07	0.00	0.00	0.07	0.11	0.00	1.06	1.00	0.97	0.03
disease	null	W4	Sequential trials, ITT	V4_within	-0.05	0.00	0.00	-0.05	0.12	0.00	1.23	1.03	0.94	0.06
disease	null	W4	CCW, A vs B2	V1_ignore	0.22	0.00	0.00	0.22	0.21	0.00	2.10	1.09	0.94	0.06
disease	null	W4	CCW, A vs B2	V2_cluster	0.22	0.00	0.00	0.22	0.21	0.00	2.10	1.10	0.94	0.06
disease	null	W4	CCW, A vs B2	V3_random	0.30	0.00	0.00	0.30	0.22	0.00	2.15	1.10	0.95	0.05
disease	null	W4	CCW, A vs B2	V4_within	0.24	0.00	0.00	0.24	0.25	0.00	2.52	1.12	0.92	0.08
disease	null	W4	CCW, A vs B1 (reference)	V1_ignore	0.25	0.00	0.00	0.25	0.21	0.00	2.11	1.09	0.95	0.05
disease	null	W4	CCW, A vs B1 (reference)	V2_cluster	0.25	0.00	0.00	0.25	0.21	0.00	2.11	1.09	0.94	0.06
disease	null	W4	CCW, A vs B1 (reference)	V3_random	0.28	0.00	0.00	0.28	0.22	0.00	2.16	1.09	0.95	0.05
disease	null	W4	CCW, A vs B1 (reference)	V4_within	0.23	0.00	0.00	0.23	0.25	0.00	2.52	1.12	0.92	0.08
disease	null	W5	Naive ‘ever early PVI’	V1_ignore	5.06	1.33	0.00	3.73	0.13	1.33	0.98	1.03	0.00	1.00
disease	null	W5	Naive ‘ever early PVI’	V2_cluster	5.06	1.33	0.00	3.73	0.13	1.33	0.98	1.03	0.01	1.00
disease	null	W5	Naive ‘ever early PVI’	V3_random	5.13	1.33	0.00	3.80	0.13	1.33	0.99	1.05	0.00	1.00
disease	null	W5	Naive ‘ever early PVI’	V4_within	4.76	1.33	0.00	3.43	0.14	1.33	1.15	1.08	0.15	0.98
disease	null	W5	Landmark at 6 months	V1_ignore	2.80	-0.34	0.00	3.14	0.08	-0.34	0.94	1.08	0.06	0.83
disease	null	W5	Landmark at 6 months	V2_cluster	2.80	-0.34	0.00	3.14	0.08	-0.34	0.94	1.07	0.07	0.82
disease	null	W5	Landmark at 6 months	V3_random	2.82	-0.34	0.00	3.16	0.08	-0.34	0.95	1.08	0.06	0.81
disease	null	W5	Landmark at 6 months	V4_within	2.77	-0.34	0.00	3.11	0.10	-0.34	1.15	1.10	0.25	0.62
disease	null	W5	Sequential trials, ITT	V1_ignore	3.43	0.00	0.00	3.43	0.09	0.00	0.92	1.07	0.05	0.95
disease	null	W5	Sequential trials, ITT	V2_cluster	3.43	0.00	0.00	3.43	0.09	0.00	0.92	1.07	0.04	0.96
disease	null	W5	Sequential trials, ITT	V3_random	3.43	0.00	0.00	3.43	0.09	0.00	0.92	1.09	0.05	0.95
disease	null	W5	Sequential trials, ITT	V4_within	3.40	0.00	0.00	3.40	0.11	0.00	1.08	1.12	0.10	0.90
disease	null	W5	CCW, A vs B2	V1_ignore	2.89	0.00	0.00	2.89	0.22	0.00	2.20	0.99	0.77	0.23
disease	null	W5	CCW, A vs B2	V2_cluster	2.89	0.00	0.00	2.89	0.22	0.00	2.20	0.99	0.76	0.24
disease	null	W5	CCW, A vs B2	V3_random	2.91	0.00	0.00	2.91	0.22	0.00	2.25	0.98	0.78	0.22
disease	null	W5	CCW, A vs B2	V4_within	2.95	0.00	0.00	2.95	0.27	0.00	2.67	1.00	0.85	0.15
disease	null	W5	CCW, A vs B1 (reference)	V1_ignore	2.89	0.00	0.00	2.89	0.22	0.00	2.20	0.99	0.77	0.23
disease	null	W5	CCW, A vs B1 (reference)	V2_cluster	2.89	0.00	0.00	2.89	0.22	0.00	2.20	0.99	0.76	0.24
disease	null	W5	CCW, A vs B1 (reference)	V3_random	2.91	0.00	0.00	2.91	0.22	0.00	2.25	0.98	0.78	0.22
disease	null	W5	CCW, A vs B1 (reference)	V4_within	2.95	0.00	0.00	2.95	0.27	0.00	2.67	1.00	0.84	0.16
disease	null	WR	Naive ‘ever early PVI’	V1_ignore	5.59	10.57	0.00	-4.98	0.82	10.57	1.21	0.95	0.03	1.00
disease	null	WR	Naive ‘ever early PVI’	V2_cluster	5.59	10.57	0.00	-4.98	0.82	10.57	1.21	0.95	0.03	1.00
disease	null	WR	Naive ‘ever early PVI’	V3_random	6.18	10.57	0.00	-4.39	0.80	10.57	1.60	0.99	0.20	0.99
disease	null	WR	Naive ‘ever early PVI’	V4_within	4.61	10.57	0.00	-5.96	0.84	10.57	1.71	0.98	0.07	0.83
disease	null	WR	Landmark at 6 months	V1_ignore	3.44	0.03	0.00	3.40	0.40	0.03	1.11	1.02	0.08	0.92
disease	null	WR	Landmark at 6 months	V2_cluster	3.44	0.03	0.00	3.40	0.40	0.03	1.11	1.01	0.07	0.93
disease	null	WR	Landmark at 6 months	V3_random	2.98	0.03	0.00	2.95	0.37	0.03	1.52	0.95	0.43	0.57
disease	null	WR	Landmark at 6 months	V4_within	2.56	0.03	0.00	2.53	0.38	0.03	1.79	0.95	0.69	0.31
disease	null	WR	Sequential trials, ITT	V1_ignore	4.01	0.00	0.00	4.01	0.12	0.00	1.15	0.95	0.03	0.97
disease	null	WR	Sequential trials, ITT	V2_cluster	4.01	0.00	0.00	4.01	0.12	0.00	1.15	0.95	0.03	0.97
disease	null	WR	Sequential trials, ITT	V3_random	3.63	0.00	0.00	3.63	0.14	0.00	1.44	0.98	0.23	0.77
disease	null	WR	Sequential trials, ITT	V4_within	3.30	0.00	0.00	3.30	0.16	0.00	1.61	0.98	0.40	0.60
disease	null	WR	CCW, A vs B2	V1_ignore	2.84	0.00	0.00	2.84	0.25	0.00	2.52	1.00	0.85	0.15
disease	null	WR	CCW, A vs B2	V2_cluster	2.84	0.00	0.00	2.84	0.25	0.00	2.52	1.00	0.85	0.15
disease	null	WR	CCW, A vs B2	V3_random	2.61	0.00	0.00	2.61	0.31	0.00	3.06	0.96	0.91	0.09
disease	null	WR	CCW, A vs B2	V4_within	2.31	0.00	0.00	2.31	0.32	0.00	3.20	0.99	0.91	0.09
disease	null	WR	CCW, A vs B1 (reference)	V1_ignore	2.80	0.00	0.00	2.80	0.25	0.00	2.53	1.00	0.85	0.15
disease	null	WR	CCW, A vs B1 (reference)	V2_cluster	2.80	0.00	0.00	2.80	0.25	0.00	2.53	1.00	0.85	0.15
disease	null	WR	CCW, A vs B1 (reference)	V3_random	2.55	0.00	0.00	2.55	0.31	0.00	3.07	0.95	0.91	0.09
disease	null	WR	CCW, A vs B1 (reference)	V4_within	2.21	0.00	0.00	2.21	0.32	0.00	3.22	0.98	0.91	0.09
male	benefit_harm	W0	Naive ‘ever early PVI’	V1_ignore	20.48	20.59	17.36	-0.11	0.09	3.23	1.68	1.13	0.98	1.00
male	benefit_harm	W0	Naive ‘ever early PVI’	V2_cluster	20.48	20.59	17.36	-0.11	0.09	3.23	1.68	1.13	0.97	1.00
male	benefit_harm	W0	Naive ‘ever early PVI’	V3_random	20.54	20.59	17.36	-0.04	0.09	3.23	1.74	1.11	0.97	1.00
male	benefit_harm	W0	Naive ‘ever early PVI’	V4_within	19.70	20.59	17.36	-0.89	0.17	3.23	2.39	1.00	0.90	1.00
male	benefit_harm	W0	Landmark at 6 months	V1_ignore	21.06	20.76	17.36	0.29	0.24	3.40	5.88	0.91	0.91	0.99
male	benefit_harm	W0	Landmark at 6 months	V2_cluster	21.06	20.76	17.36	0.29	0.24	3.40	5.88	0.90	0.92	0.99
male	benefit_harm	W0	Landmark at 6 months	V3_random	21.03	20.76	17.36	0.27	0.24	3.40	5.92	0.90	0.92	0.99
male	benefit_harm	W0	Landmark at 6 months	V4_within	20.97	20.76	17.36	0.21	0.60	3.40	8.37	0.84	0.90	0.90
male	benefit_harm	W0	Sequential trials, ITT	V1_ignore	19.52	19.27	17.36	0.26	0.17	1.91	1.66	1.09	0.98	1.00
male	benefit_harm	W0	Sequential trials, ITT	V2_cluster	19.52	19.27	17.36	0.26	0.17	1.91	1.66	1.08	0.98	1.00
male	benefit_harm	W0	Sequential trials, ITT	V3_random	19.44	19.27	17.36	0.17	0.17	1.91	1.73	1.06	0.97	1.00
male	benefit_harm	W0	Sequential trials, ITT	V4_within	18.97	19.27	17.36	-0.29	0.23	1.91	2.33	0.93	0.94	1.00
male	benefit_harm	W0	CCW, A vs B2	V1_ignore	17.71	17.55	17.36	0.16	0.44	0.19	4.39	0.93	0.92	1.00
male	benefit_harm	W0	CCW, A vs B2	V2_cluster	17.71	17.55	17.36	0.16	0.44	0.19	4.39	0.92	0.92	1.00
male	benefit_harm	W0	CCW, A vs B2	V3_random	17.71	17.55	17.36	0.15	0.44	0.19	4.39	0.93	0.91	1.00
male	benefit_harm	W0	CCW, A vs B2	V4_within	17.57	17.55	17.36	0.02	0.49	0.19	4.91	0.98	0.93	0.99
male	benefit_harm	W0	CCW, A vs B1 (reference)	V1_ignore	17.52	17.36	17.36	0.17	0.44	0.00	4.39	0.92	0.92	1.00
male	benefit_harm	W0	CCW, A vs B1 (reference)	V2_cluster	17.52	17.36	17.36	0.17	0.44	0.00	4.39	0.92	0.92	1.00
male	benefit_harm	W0	CCW, A vs B1 (reference)	V3_random	17.52	17.36	17.36	0.16	0.44	0.00	4.40	0.93	0.91	1.00
male	benefit_harm	W0	CCW, A vs B1 (reference)	V4_within	17.37	17.36	17.36	0.01	0.49	0.00	4.91	0.98	0.93	0.98
male	benefit_harm	W1	Naive ‘ever early PVI’	V1_ignore	25.03	22.76	19.95	2.27	0.13	2.81	2.25	0.88	0.82	1.00
male	benefit_harm	W1	Naive ‘ever early PVI’	V2_cluster	25.03	22.76	19.95	2.27	0.13	2.81	2.25	0.97	0.85	1.00
male	benefit_harm	W1	Naive ‘ever early PVI’	V3_random	24.49	22.76	19.95	1.73	0.10	2.81	2.17	0.99	0.90	1.00
male	benefit_harm	W1	Naive ‘ever early PVI’	V4_within	22.92	22.76	19.95	0.16	0.14	2.81	2.55	1.02	0.96	1.00
male	benefit_harm	W1	Landmark at 6 months	V1_ignore	25.57	21.61	19.95	3.96	0.28	1.67	6.35	0.88	0.85	0.98
male	benefit_harm	W1	Landmark at 6 months	V2_cluster	25.57	21.61	19.95	3.96	0.28	1.67	6.35	0.90	0.86	0.98
male	benefit_harm	W1	Landmark at 6 months	V3_random	25.36	21.61	19.95	3.74	0.26	1.67	6.30	0.90	0.86	0.98
male	benefit_harm	W1	Landmark at 6 months	V4_within	23.70	21.61	19.95	2.09	0.59	1.67	8.40	0.85	0.90	0.91
male	benefit_harm	W1	Sequential trials, ITT	V1_ignore	24.20	21.75	19.95	2.45	0.22	1.80	2.20	0.86	0.74	1.00
male	benefit_harm	W1	Sequential trials, ITT	V2_cluster	24.20	21.75	19.95	2.45	0.22	1.80	2.20	0.95	0.80	1.00
male	benefit_harm	W1	Sequential trials, ITT	V3_random	23.51	21.75	19.95	1.76	0.21	1.80	2.13	0.97	0.88	1.00
male	benefit_harm	W1	Sequential trials, ITT	V4_within	22.30	21.75	19.95	0.54	0.24	1.80	2.44	0.99	0.94	1.00
male	benefit_harm	W1	CCW, A vs B2	V1_ignore	22.36	20.21	19.95	2.15	0.47	0.26	4.70	0.89	0.85	1.00
male	benefit_harm	W1	CCW, A vs B2	V2_cluster	22.36	20.21	19.95	2.15	0.47	0.26	4.70	0.91	0.87	1.00
male	benefit_harm	W1	CCW, A vs B2	V3_random	21.91	20.21	19.95	1.70	0.47	0.26	4.74	0.91	0.88	1.00
male	benefit_harm	W1	CCW, A vs B2	V4_within	20.98	20.21	19.95	0.77	0.56	0.26	5.59	0.89	0.87	1.00
male	benefit_harm	W1	CCW, A vs B1 (reference)	V1_ignore	22.10	19.95	19.95	2.15	0.47	0.00	4.70	0.89	0.85	1.00
male	benefit_harm	W1	CCW, A vs B1 (reference)	V2_cluster	22.10	19.95	19.95	2.15	0.47	0.00	4.70	0.91	0.87	1.00
male	benefit_harm	W1	CCW, A vs B1 (reference)	V3_random	21.65	19.95	19.95	1.70	0.47	0.00	4.75	0.91	0.88	1.00
male	benefit_harm	W1	CCW, A vs B1 (reference)	V4_within	20.69	19.95	19.95	0.74	0.56	0.00	5.59	0.89	0.87	0.99
male	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V1_ignore	23.81	24.02	20.65	-0.21	0.12	3.37	1.86	1.05	0.93	1.00
male	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V2_cluster	23.81	24.02	20.65	-0.21	0.12	3.37	1.86	1.15	0.98	1.00
male	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V3_random	23.95	24.02	20.65	-0.08	0.09	3.37	1.92	1.12	0.96	1.00
male	benefit_harm	W1_rho0	Naive ‘ever early PVI’	V4_within	23.34	24.02	20.65	-0.68	0.14	3.37	2.58	1.03	0.94	1.00
male	benefit_harm	W1_rho0	Landmark at 6 months	V1_ignore	25.30	23.91	20.65	1.40	0.29	3.25	6.00	0.92	0.93	1.00
male	benefit_harm	W1_rho0	Landmark at 6 months	V2_cluster	25.30	23.91	20.65	1.40	0.29	3.25	6.00	0.93	0.94	1.00
male	benefit_harm	W1_rho0	Landmark at 6 months	V3_random	25.19	23.91	20.65	1.28	0.28	3.25	6.00	0.93	0.92	1.00
male	benefit_harm	W1_rho0	Landmark at 6 months	V4_within	23.47	23.91	20.65	-0.44	0.64	3.25	8.29	0.91	0.91	0.89
male	benefit_harm	W1_rho0	Sequential trials, ITT	V1_ignore	22.93	22.55	20.65	0.39	0.18	1.89	1.84	1.02	0.96	1.00
male	benefit_harm	W1_rho0	Sequential trials, ITT	V2_cluster	22.93	22.55	20.65	0.39	0.18	1.89	1.84	1.12	0.98	1.00
male	benefit_harm	W1_rho0	Sequential trials, ITT	V3_random	22.93	22.55	20.65	0.39	0.19	1.89	1.90	1.09	0.98	1.00
male	benefit_harm	W1_rho0	Sequential trials, ITT	V4_within	22.61	22.55	20.65	0.06	0.25	1.89	2.47	0.98	0.94	1.00
male	benefit_harm	W1_rho0	CCW, A vs B2	V1_ignore	21.33	20.89	20.65	0.44	0.43	0.24	4.28	0.98	0.98	1.00
male	benefit_harm	W1_rho0	CCW, A vs B2	V2_cluster	21.33	20.89	20.65	0.44	0.43	0.24	4.28	1.00	0.98	1.00
male	benefit_harm	W1_rho0	CCW, A vs B2	V3_random	21.44	20.89	20.65	0.54	0.45	0.24	4.46	0.98	0.94	1.00
male	benefit_harm	W1_rho0	CCW, A vs B2	V4_within	21.43	20.89	20.65	0.54	0.54	0.24	5.43	0.96	0.94	0.99
male	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	21.09	20.65	20.65	0.44	0.43	0.00	4.28	0.98	0.98	1.00
male	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	21.09	20.65	20.65	0.44	0.43	0.00	4.28	1.00	0.98	1.00
male	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V3_random	21.20	20.65	20.65	0.54	0.45	0.00	4.46	0.98	0.94	1.00
male	benefit_harm	W1_rho0	CCW, A vs B1 (reference)	V4_within	21.17	20.65	20.65	0.52	0.54	0.00	5.43	0.96	0.94	0.99
male	benefit_harm	W2	Naive ‘ever early PVI’	V1_ignore	21.59	27.04	17.96	-5.46	0.83	9.09	1.98	0.97	0.23	1.00
male	benefit_harm	W2	Naive ‘ever early PVI’	V2_cluster	21.59	27.04	17.96	-5.46	0.83	9.09	1.98	0.97	0.22	1.00
male	benefit_harm	W2	Naive ‘ever early PVI’	V3_random	22.12	27.04	17.96	-4.92	0.84	9.09	2.99	0.99	0.53	1.00
male	benefit_harm	W2	Naive ‘ever early PVI’	V4_within	19.76	27.04	17.96	-7.28	0.89	9.09	3.56	0.99	0.42	1.00
male	benefit_harm	W2	Landmark at 6 months	V1_ignore	21.61	18.83	17.96	2.77	1.07	0.87	5.12	1.05	0.94	0.98
male	benefit_harm	W2	Landmark at 6 months	V2_cluster	21.61	18.83	17.96	2.77	1.07	0.87	5.12	1.04	0.92	0.99
male	benefit_harm	W2	Landmark at 6 months	V3_random	22.09	18.83	17.96	3.26	1.01	0.87	5.51	1.05	0.92	0.97
male	benefit_harm	W2	Landmark at 6 months	V4_within	21.17	18.83	17.96	2.34	1.15	0.87	8.19	0.92	0.92	0.89
male	benefit_harm	W2	Sequential trials, ITT	V1_ignore	20.53	19.92	17.96	0.62	0.19	1.96	1.93	0.95	0.94	1.00
male	benefit_harm	W2	Sequential trials, ITT	V2_cluster	20.53	19.92	17.96	0.62	0.19	1.96	1.93	0.94	0.94	1.00
male	benefit_harm	W2	Sequential trials, ITT	V3_random	19.88	19.92	17.96	-0.04	0.27	1.96	2.66	0.95	0.92	1.00
male	benefit_harm	W2	Sequential trials, ITT	V4_within	19.07	19.92	17.96	-0.84	0.30	1.96	2.97	0.94	0.91	1.00
male	benefit_harm	W2	CCW, A vs B2	V1_ignore	18.59	18.22	17.96	0.36	0.41	0.27	4.11	1.03	0.96	1.00
male	benefit_harm	W2	CCW, A vs B2	V2_cluster	18.59	18.22	17.96	0.36	0.41	0.27	4.11	1.01	0.96	1.00
male	benefit_harm	W2	CCW, A vs B2	V3_random	18.73	18.22	17.96	0.50	0.59	0.27	5.91	0.95	0.90	0.96
male	benefit_harm	W2	CCW, A vs B2	V4_within	18.88	18.22	17.96	0.65	0.75	0.27	7.46	0.86	0.90	0.91
male	benefit_harm	W2	CCW, A vs B1 (reference)	V1_ignore	18.37	17.96	17.96	0.41	0.41	0.00	4.11	1.03	0.97	1.00
male	benefit_harm	W2	CCW, A vs B1 (reference)	V2_cluster	18.37	17.96	17.96	0.41	0.41	0.00	4.11	1.02	0.96	1.00
male	benefit_harm	W2	CCW, A vs B1 (reference)	V3_random	18.47	17.96	17.96	0.52	0.59	0.00	5.90	0.95	0.90	0.96
male	benefit_harm	W2	CCW, A vs B1 (reference)	V4_within	18.41	17.96	17.96	0.45	0.75	0.00	7.46	0.86	0.91	0.89
male	benefit_harm	W3	Naive ‘ever early PVI’	V1_ignore	23.34	21.85	11.26	1.48	0.86	10.59	2.35	0.83	0.80	1.00
male	benefit_harm	W3	Naive ‘ever early PVI’	V2_cluster	23.34	21.85	11.26	1.48	0.86	10.59	2.35	0.90	0.83	1.00
male	benefit_harm	W3	Naive ‘ever early PVI’	V3_random	18.80	21.85	11.26	-3.05	0.79	10.59	3.02	0.96	0.76	1.00
male	benefit_harm	W3	Naive ‘ever early PVI’	V4_within	15.60	21.85	11.26	-6.25	0.84	10.59	3.44	0.96	0.44	0.99
male	benefit_harm	W3	Landmark at 6 months	V1_ignore	21.76	14.64	11.26	7.12	0.84	3.38	5.55	0.97	0.80	0.98
male	benefit_harm	W3	Landmark at 6 months	V2_cluster	21.76	14.64	11.26	7.12	0.84	3.38	5.55	0.97	0.78	0.98
male	benefit_harm	W3	Landmark at 6 months	V3_random	19.73	14.64	11.26	5.09	0.72	3.38	5.99	0.92	0.84	0.97
male	benefit_harm	W3	Landmark at 6 months	V4_within	17.68	14.64	11.26	3.03	0.84	3.38	9.04	0.76	0.85	0.74
male	benefit_harm	W3	Sequential trials, ITT	V1_ignore	22.17	12.63	11.26	9.54	0.22	1.37	2.21	0.84	0.00	1.00
male	benefit_harm	W3	Sequential trials, ITT	V2_cluster	22.17	12.63	11.26	9.54	0.22	1.37	2.21	0.92	0.00	1.00
male	benefit_harm	W3	Sequential trials, ITT	V3_random	16.25	12.63	11.26	3.62	0.25	1.37	2.49	0.96	0.68	1.00
male	benefit_harm	W3	Sequential trials, ITT	V4_within	14.82	12.63	11.26	2.19	0.28	1.37	2.78	0.94	0.88	1.00
male	benefit_harm	W3	CCW, A vs B2	V1_ignore	18.63	11.57	11.26	7.07	0.45	0.30	4.45	0.96	0.65	1.00
male	benefit_harm	W3	CCW, A vs B2	V2_cluster	18.63	11.57	11.26	7.07	0.45	0.30	4.45	0.96	0.64	1.00
male	benefit_harm	W3	CCW, A vs B2	V3_random	14.81	11.57	11.26	3.24	0.58	0.30	5.79	0.92	0.86	0.84
male	benefit_harm	W3	CCW, A vs B2	V4_within	14.02	11.57	11.26	2.46	0.67	0.30	6.67	0.87	0.87	0.70
male	benefit_harm	W3	CCW, A vs B1 (reference)	V1_ignore	18.40	11.26	11.26	7.14	0.45	0.00	4.45	0.96	0.64	1.00
male	benefit_harm	W3	CCW, A vs B1 (reference)	V2_cluster	18.40	11.26	11.26	7.14	0.45	0.00	4.45	0.96	0.64	1.00
male	benefit_harm	W3	CCW, A vs B1 (reference)	V3_random	14.52	11.26	11.26	3.26	0.58	0.00	5.80	0.92	0.86	0.81
male	benefit_harm	W3	CCW, A vs B1 (reference)	V4_within	13.48	11.26	11.26	2.22	0.67	0.00	6.68	0.87	0.88	0.66
male	benefit_harm	W4	Naive ‘ever early PVI’	V1_ignore	19.23	19.51	16.42	-0.29	0.10	3.10	1.76	1.08	0.95	1.00
male	benefit_harm	W4	Naive ‘ever early PVI’	V2_cluster	19.23	19.51	16.42	-0.29	0.10	3.10	1.76	1.08	0.94	1.00
male	benefit_harm	W4	Naive ‘ever early PVI’	V3_random	19.37	19.51	16.42	-0.14	0.09	3.10	1.81	1.08	0.96	1.00
male	benefit_harm	W4	Naive ‘ever early PVI’	V4_within	18.72	19.51	16.42	-0.80	0.15	3.10	2.25	1.08	0.95	1.00
male	benefit_harm	W4	Landmark at 6 months	V1_ignore	19.24	19.15	16.42	0.09	0.22	2.73	5.57	0.94	0.95	0.99
male	benefit_harm	W4	Landmark at 6 months	V2_cluster	19.24	19.15	16.42	0.09	0.22	2.73	5.57	0.94	0.94	0.99
male	benefit_harm	W4	Landmark at 6 months	V3_random	19.18	19.15	16.42	0.03	0.21	2.73	5.53	0.95	0.93	0.99
male	benefit_harm	W4	Landmark at 6 months	V4_within	17.59	19.15	16.42	-1.56	0.51	2.73	8.20	0.84	0.87	0.78
male	benefit_harm	W4	Sequential trials, ITT	V1_ignore	18.28	18.34	16.42	-0.06	0.17	1.92	1.73	1.05	0.95	1.00
male	benefit_harm	W4	Sequential trials, ITT	V2_cluster	18.28	18.34	16.42	-0.06	0.17	1.92	1.73	1.05	0.96	1.00
male	benefit_harm	W4	Sequential trials, ITT	V3_random	18.29	18.34	16.42	-0.05	0.18	1.92	1.78	1.05	0.97	1.00
male	benefit_harm	W4	Sequential trials, ITT	V4_within	18.04	18.34	16.42	-0.30	0.22	1.92	2.16	1.02	0.94	1.00
male	benefit_harm	W4	CCW, A vs B2	V1_ignore	16.90	17.50	16.42	-0.60	0.39	1.08	3.88	1.03	0.92	1.00
male	benefit_harm	W4	CCW, A vs B2	V2_cluster	16.90	17.50	16.42	-0.60	0.39	1.08	3.88	1.02	0.93	1.00
male	benefit_harm	W4	CCW, A vs B2	V3_random	16.95	17.50	16.42	-0.55	0.39	1.08	3.91	1.03	0.93	1.00
male	benefit_harm	W4	CCW, A vs B2	V4_within	16.52	17.50	16.42	-0.98	0.47	1.08	4.66	1.00	0.91	0.97
male	benefit_harm	W4	CCW, A vs B1 (reference)	V1_ignore	15.86	16.42	16.42	-0.55	0.39	0.00	3.86	1.03	0.93	1.00
male	benefit_harm	W4	CCW, A vs B1 (reference)	V2_cluster	15.86	16.42	16.42	-0.55	0.39	0.00	3.86	1.03	0.93	1.00
male	benefit_harm	W4	CCW, A vs B1 (reference)	V3_random	15.86	16.42	16.42	-0.56	0.39	0.00	3.90	1.04	0.93	1.00
male	benefit_harm	W4	CCW, A vs B1 (reference)	V4_within	15.35	16.42	16.42	-1.07	0.47	0.00	4.66	1.00	0.91	0.95
male	benefit_harm	W5	Naive ‘ever early PVI’	V1_ignore	26.90	20.55	17.36	6.35	0.20	3.20	1.42	0.98	0.00	1.00
male	benefit_harm	W5	Naive ‘ever early PVI’	V2_cluster	26.90	20.55	17.36	6.35	0.20	3.20	1.42	0.98	0.00	1.00
male	benefit_harm	W5	Naive ‘ever early PVI’	V3_random	26.91	20.55	17.36	6.36	0.19	3.20	1.46	0.97	0.00	1.00
male	benefit_harm	W5	Naive ‘ever early PVI’	V4_within	26.61	20.55	17.36	6.06	0.20	3.20	1.77	0.96	0.05	1.00
male	benefit_harm	W5	Landmark at 6 months	V1_ignore	27.21	21.13	17.36	6.08	0.58	3.77	1.41	1.01	0.00	1.00
male	benefit_harm	W5	Landmark at 6 months	V2_cluster	27.21	21.13	17.36	6.08	0.58	3.77	1.41	1.01	0.00	1.00
male	benefit_harm	W5	Landmark at 6 months	V3_random	27.17	21.13	17.36	6.04	0.58	3.77	1.44	1.01	0.00	1.00
male	benefit_harm	W5	Landmark at 6 months	V4_within	27.07	21.13	17.36	5.94	0.61	3.77	1.80	0.97	0.09	1.00
male	benefit_harm	W5	Sequential trials, ITT	V1_ignore	25.01	19.27	17.36	5.75	0.15	1.91	1.52	0.95	0.02	1.00
male	benefit_harm	W5	Sequential trials, ITT	V2_cluster	25.01	19.27	17.36	5.75	0.15	1.91	1.52	0.95	0.02	1.00
male	benefit_harm	W5	Sequential trials, ITT	V3_random	24.96	19.27	17.36	5.70	0.16	1.91	1.57	0.94	0.03	1.00
male	benefit_harm	W5	Sequential trials, ITT	V4_within	24.72	19.27	17.36	5.45	0.19	1.91	1.93	0.91	0.13	1.00
male	benefit_harm	W5	CCW, A vs B2	V1_ignore	22.72	17.55	17.36	5.17	0.33	0.19	3.34	0.97	0.62	1.00
male	benefit_harm	W5	CCW, A vs B2	V2_cluster	22.72	17.55	17.36	5.17	0.33	0.19	3.34	0.97	0.63	1.00
male	benefit_harm	W5	CCW, A vs B2	V3_random	22.87	17.55	17.36	5.31	0.34	0.19	3.36	0.98	0.58	1.00
male	benefit_harm	W5	CCW, A vs B2	V4_within	23.15	17.55	17.36	5.60	0.41	0.19	4.12	0.95	0.67	1.00
male	benefit_harm	W5	CCW, A vs B1 (reference)	V1_ignore	22.54	17.36	17.36	5.18	0.33	0.00	3.34	0.97	0.62	1.00
male	benefit_harm	W5	CCW, A vs B1 (reference)	V2_cluster	22.54	17.36	17.36	5.18	0.33	0.00	3.34	0.97	0.63	1.00
male	benefit_harm	W5	CCW, A vs B1 (reference)	V3_random	22.68	17.36	17.36	5.33	0.34	0.00	3.36	0.98	0.58	1.00
male	benefit_harm	W5	CCW, A vs B1 (reference)	V4_within	22.95	17.36	17.36	5.59	0.41	0.00	4.12	0.95	0.67	1.00
male	benefit_harm	WR	Naive ‘ever early PVI’	V1_ignore	34.09	25.32	13.73	8.78	1.05	11.59	2.19	0.73	0.00	1.00
male	benefit_harm	WR	Naive ‘ever early PVI’	V2_cluster	34.09	25.32	13.73	8.78	1.05	11.59	2.19	1.05	0.01	1.00
male	benefit_harm	WR	Naive ‘ever early PVI’	V3_random	28.65	25.32	13.73	3.33	1.00	11.59	2.05	1.09	0.73	1.00
male	benefit_harm	WR	Naive ‘ever early PVI’	V4_within	26.55	25.32	13.73	1.23	1.02	11.59	2.26	1.11	0.94	1.00
male	benefit_harm	WR	Landmark at 6 months	V1_ignore	34.42	17.84	13.73	16.58	1.10	4.11	2.22	0.74	0.00	1.00
male	benefit_harm	WR	Landmark at 6 months	V2_cluster	34.42	17.84	13.73	16.58	1.10	4.11	2.22	1.05	0.00	1.00
male	benefit_harm	WR	Landmark at 6 months	V3_random	28.31	17.84	13.73	10.48	1.09	4.11	2.10	1.09	0.00	1.00
male	benefit_harm	WR	Landmark at 6 months	V4_within	27.20	17.84	13.73	9.36	1.10	4.11	2.34	1.11	0.01	1.00
male	benefit_harm	WR	Sequential trials, ITT	V1_ignore	32.48	15.12	13.73	17.36	0.23	1.39	2.34	0.70	0.00	1.00
male	benefit_harm	WR	Sequential trials, ITT	V2_cluster	32.48	15.12	13.73	17.36	0.23	1.39	2.34	1.00	0.00	1.00
male	benefit_harm	WR	Sequential trials, ITT	V3_random	26.01	15.12	13.73	10.89	0.22	1.39	2.24	1.01	0.00	1.00
male	benefit_harm	WR	Sequential trials, ITT	V4_within	24.59	15.12	13.73	9.48	0.24	1.39	2.44	1.02	0.01	1.00
male	benefit_harm	WR	CCW, A vs B2	V1_ignore	28.91	14.11	13.73	14.79	0.45	0.38	4.55	0.85	0.05	1.00
male	benefit_harm	WR	CCW, A vs B2	V2_cluster	28.91	14.11	13.73	14.79	0.45	0.38	4.55	0.91	0.07	1.00
male	benefit_harm	WR	CCW, A vs B2	V3_random	24.27	14.11	13.73	10.15	0.48	0.38	4.79	0.98	0.43	1.00
male	benefit_harm	WR	CCW, A vs B2	V4_within	23.96	14.11	13.73	9.85	0.54	0.38	5.42	0.97	0.53	1.00
male	benefit_harm	WR	CCW, A vs B1 (reference)	V1_ignore	28.60	13.73	13.73	14.87	0.45	0.00	4.53	0.85	0.04	1.00
male	benefit_harm	WR	CCW, A vs B1 (reference)	V2_cluster	28.60	13.73	13.73	14.87	0.45	0.00	4.53	0.91	0.07	1.00
male	benefit_harm	WR	CCW, A vs B1 (reference)	V3_random	23.87	13.73	13.73	10.14	0.48	0.00	4.77	0.98	0.42	1.00
male	benefit_harm	WR	CCW, A vs B1 (reference)	V4_within	23.20	13.73	13.73	9.47	0.54	0.00	5.38	0.97	0.56	1.00
male	harm	W0	Naive ‘ever early PVI’	V1_ignore	23.13	23.33	20.68	-0.20	0.09	2.66	1.97	0.99	0.95	1.00
male	harm	W0	Naive ‘ever early PVI’	V2_cluster	23.13	23.33	20.68	-0.20	0.09	2.66	1.97	0.98	0.94	1.00
male	harm	W0	Naive ‘ever early PVI’	V3_random	23.27	23.33	20.68	-0.07	0.08	2.66	2.04	0.97	0.94	1.00
male	harm	W0	Naive ‘ever early PVI’	V4_within	22.58	23.33	20.68	-0.75	0.15	2.66	2.44	1.01	0.93	1.00
male	harm	W0	Landmark at 6 months	V1_ignore	24.73	24.67	20.68	0.06	0.21	4.00	4.71	0.98	0.97	1.00
male	harm	W0	Landmark at 6 months	V2_cluster	24.73	24.67	20.68	0.06	0.21	4.00	4.71	0.98	0.97	1.00
male	harm	W0	Landmark at 6 months	V3_random	24.67	24.67	20.68	0.00	0.19	4.00	4.84	0.96	0.96	1.00
male	harm	W0	Landmark at 6 months	V4_within	24.17	24.67	20.68	-0.50	0.38	4.00	6.49	0.89	0.92	0.96
male	harm	W0	Sequential trials, ITT	V1_ignore	22.15	22.23	20.68	-0.07	0.19	1.55	1.89	0.98	0.93	1.00
male	harm	W0	Sequential trials, ITT	V2_cluster	22.15	22.23	20.68	-0.07	0.19	1.55	1.89	0.98	0.94	1.00
male	harm	W0	Sequential trials, ITT	V3_random	22.16	22.23	20.68	-0.07	0.20	1.55	2.01	0.95	0.94	1.00
male	harm	W0	Sequential trials, ITT	V4_within	21.81	22.23	20.68	-0.41	0.24	1.55	2.40	0.95	0.93	1.00
male	harm	W0	CCW, A vs B2	V1_ignore	21.22	20.98	20.68	0.24	0.43	0.30	4.35	0.97	0.95	1.00
male	harm	W0	CCW, A vs B2	V2_cluster	21.22	20.98	20.68	0.24	0.43	0.30	4.35	0.97	0.92	1.00
male	harm	W0	CCW, A vs B2	V3_random	21.23	20.98	20.68	0.25	0.45	0.30	4.54	0.95	0.96	1.00
male	harm	W0	CCW, A vs B2	V4_within	21.40	20.98	20.68	0.42	0.55	0.30	5.51	0.94	0.91	1.00
male	harm	W0	CCW, A vs B1 (reference)	V1_ignore	20.93	20.68	20.68	0.25	0.44	0.00	4.35	0.97	0.94	1.00
male	harm	W0	CCW, A vs B1 (reference)	V2_cluster	20.93	20.68	20.68	0.25	0.44	0.00	4.35	0.97	0.92	1.00
male	harm	W0	CCW, A vs B1 (reference)	V3_random	20.94	20.68	20.68	0.26	0.45	0.00	4.54	0.95	0.96	1.00
male	harm	W0	CCW, A vs B1 (reference)	V4_within	21.08	20.68	20.68	0.41	0.55	0.00	5.52	0.94	0.91	1.00
male	harm	W1	Naive ‘ever early PVI’	V1_ignore	25.95	24.73	21.55	1.22	0.12	3.18	1.80	1.12	0.95	1.00
male	harm	W1	Naive ‘ever early PVI’	V2_cluster	25.95	24.73	21.55	1.22	0.12	3.18	1.80	1.17	0.95	1.00
male	harm	W1	Naive ‘ever early PVI’	V3_random	25.62	24.73	21.55	0.89	0.10	3.18	1.87	1.13	0.97	1.00
male	harm	W1	Naive ‘ever early PVI’	V4_within	24.39	24.73	21.55	-0.34	0.18	3.18	2.62	1.01	0.95	1.00
male	harm	W1	Landmark at 6 months	V1_ignore	41.61	37.41	21.55	4.19	0.35	15.87	10.29	0.61	0.88	0.99
male	harm	W1	Landmark at 6 months	V2_cluster	41.61	37.41	21.55	4.19	0.35	15.87	10.29	0.63	0.88	0.99
male	harm	W1	Landmark at 6 months	V3_random	40.37	37.41	21.55	2.96	0.29	15.87	10.37	0.61	0.86	0.99
male	harm	W1	Landmark at 6 months	V4_within	38.71	37.41	21.55	1.30	0.49	15.87	11.36	0.62	0.83	1.00
male	harm	W1	Sequential trials, ITT	V1_ignore	25.03	23.04	21.55	1.99	0.17	1.49	1.75	1.09	0.89	1.00
male	harm	W1	Sequential trials, ITT	V2_cluster	25.03	23.04	21.55	1.99	0.17	1.49	1.75	1.15	0.92	1.00
male	harm	W1	Sequential trials, ITT	V3_random	24.55	23.04	21.55	1.51	0.18	1.49	1.80	1.12	0.94	1.00
male	harm	W1	Sequential trials, ITT	V4_within	23.55	23.04	21.55	0.51	0.24	1.49	2.35	1.01	0.95	1.00
male	harm	W1	CCW, A vs B2	V1_ignore	23.52	21.89	21.55	1.63	0.44	0.34	4.35	0.97	0.92	1.00
male	harm	W1	CCW, A vs B2	V2_cluster	23.52	21.89	21.55	1.63	0.44	0.34	4.35	0.98	0.91	1.00
male	harm	W1	CCW, A vs B2	V3_random	23.10	21.89	21.55	1.21	0.44	0.34	4.41	0.97	0.92	1.00
male	harm	W1	CCW, A vs B2	V4_within	22.41	21.89	21.55	0.52	0.52	0.34	5.16	0.96	0.91	0.99
male	harm	W1	CCW, A vs B1 (reference)	V1_ignore	23.19	21.55	21.55	1.65	0.44	0.00	4.35	0.98	0.92	1.00
male	harm	W1	CCW, A vs B1 (reference)	V2_cluster	23.19	21.55	21.55	1.65	0.44	0.00	4.35	0.98	0.91	1.00
male	harm	W1	CCW, A vs B1 (reference)	V3_random	22.77	21.55	21.55	1.22	0.44	0.00	4.41	0.97	0.92	1.00
male	harm	W1	CCW, A vs B1 (reference)	V4_within	22.04	21.55	21.55	0.49	0.52	0.00	5.16	0.96	0.91	0.99
male	harm	W1_rho0	Naive ‘ever early PVI’	V1_ignore	24.83	25.06	22.33	-0.23	0.10	2.74	1.74	1.14	0.99	1.00
male	harm	W1_rho0	Naive ‘ever early PVI’	V2_cluster	24.83	25.06	22.33	-0.23	0.10	2.74	1.74	1.18	0.99	1.00
male	harm	W1_rho0	Naive ‘ever early PVI’	V3_random	24.96	25.06	22.33	-0.10	0.09	2.74	1.79	1.16	0.99	1.00
male	harm	W1_rho0	Naive ‘ever early PVI’	V4_within	24.13	25.06	22.33	-0.94	0.17	2.74	2.30	1.12	0.97	1.00
male	harm	W1_rho0	Landmark at 6 months	V1_ignore	39.19	37.80	22.33	1.39	0.31	15.47	10.02	0.65	0.83	0.99
male	harm	W1_rho0	Landmark at 6 months	V2_cluster	39.19	37.80	22.33	1.39	0.31	15.47	10.02	0.67	0.84	0.99
male	harm	W1_rho0	Landmark at 6 months	V3_random	38.75	37.80	22.33	0.95	0.26	15.47	10.06	0.66	0.83	0.99
male	harm	W1_rho0	Landmark at 6 months	V4_within	38.02	37.80	22.33	0.22	0.54	15.47	11.71	0.65	0.80	1.00
male	harm	W1_rho0	Sequential trials, ITT	V1_ignore	23.90	23.92	22.33	-0.02	0.17	1.59	1.69	1.13	0.99	1.00
male	harm	W1_rho0	Sequential trials, ITT	V2_cluster	23.90	23.92	22.33	-0.02	0.17	1.59	1.69	1.18	0.99	1.00
male	harm	W1_rho0	Sequential trials, ITT	V3_random	23.88	23.92	22.33	-0.03	0.17	1.59	1.73	1.16	0.98	1.00
male	harm	W1_rho0	Sequential trials, ITT	V4_within	23.32	23.92	22.33	-0.59	0.22	1.59	2.16	1.10	0.99	1.00
male	harm	W1_rho0	CCW, A vs B2	V1_ignore	22.90	22.65	22.33	0.25	0.45	0.32	4.46	0.95	0.92	1.00
male	harm	W1_rho0	CCW, A vs B2	V2_cluster	22.90	22.65	22.33	0.25	0.45	0.32	4.46	0.96	0.93	1.00
male	harm	W1_rho0	CCW, A vs B2	V3_random	22.91	22.65	22.33	0.26	0.45	0.32	4.54	0.96	0.92	1.00
male	harm	W1_rho0	CCW, A vs B2	V4_within	22.24	22.65	22.33	-0.41	0.53	0.32	5.33	0.93	0.91	1.00
male	harm	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	22.58	22.33	22.33	0.25	0.45	0.00	4.46	0.95	0.92	1.00
male	harm	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	22.58	22.33	22.33	0.25	0.45	0.00	4.46	0.96	0.92	1.00
male	harm	W1_rho0	CCW, A vs B1 (reference)	V3_random	22.59	22.33	22.33	0.26	0.45	0.00	4.54	0.96	0.92	1.00
male	harm	W1_rho0	CCW, A vs B1 (reference)	V4_within	21.89	22.33	22.33	-0.44	0.53	0.00	5.33	0.93	0.91	1.00
male	harm	W2	Naive ‘ever early PVI’	V1_ignore	24.52	32.00	21.28	-7.47	0.84	10.71	2.14	0.92	0.07	1.00
male	harm	W2	Naive ‘ever early PVI’	V2_cluster	24.52	32.00	21.28	-7.47	0.84	10.71	2.14	0.94	0.07	1.00
male	harm	W2	Naive ‘ever early PVI’	V3_random	25.44	32.00	21.28	-6.56	0.79	10.71	2.89	1.06	0.32	1.00
male	harm	W2	Naive ‘ever early PVI’	V4_within	22.93	32.00	21.28	-9.07	0.86	10.71	3.58	0.99	0.24	1.00
male	harm	W2	Landmark at 6 months	V1_ignore	25.59	26.09	21.28	-0.51	0.90	4.81	6.01	0.79	0.90	0.99
male	harm	W2	Landmark at 6 months	V2_cluster	25.59	26.09	21.28	-0.51	0.90	4.81	6.01	0.79	0.88	0.99
male	harm	W2	Landmark at 6 months	V3_random	25.11	26.09	21.28	-0.98	0.79	4.81	6.76	0.84	0.87	0.98
male	harm	W2	Landmark at 6 months	V4_within	23.80	26.09	21.28	-2.29	0.84	4.81	8.40	0.80	0.81	0.93
male	harm	W2	Sequential trials, ITT	V1_ignore	23.45	22.93	21.28	0.53	0.20	1.64	2.02	0.93	0.93	1.00
male	harm	W2	Sequential trials, ITT	V2_cluster	23.45	22.93	21.28	0.53	0.20	1.64	2.02	0.94	0.92	1.00
male	harm	W2	Sequential trials, ITT	V3_random	23.21	22.93	21.28	0.28	0.25	1.64	2.55	1.01	0.98	1.00
male	harm	W2	Sequential trials, ITT	V4_within	22.33	22.93	21.28	-0.59	0.29	1.64	2.89	0.99	0.94	1.00
male	harm	W2	CCW, A vs B2	V1_ignore	21.92	21.68	21.28	0.24	0.48	0.39	4.84	0.91	0.92	1.00
male	harm	W2	CCW, A vs B2	V2_cluster	21.92	21.68	21.28	0.24	0.48	0.39	4.84	0.89	0.90	1.00
male	harm	W2	CCW, A vs B2	V3_random	22.13	21.68	21.28	0.46	0.66	0.39	6.65	0.86	0.88	0.97
male	harm	W2	CCW, A vs B2	V4_within	21.69	21.68	21.28	0.02	0.75	0.39	7.53	0.83	0.92	0.91
male	harm	W2	CCW, A vs B1 (reference)	V1_ignore	21.60	21.28	21.28	0.32	0.48	0.00	4.84	0.91	0.91	1.00
male	harm	W2	CCW, A vs B1 (reference)	V2_cluster	21.60	21.28	21.28	0.32	0.48	0.00	4.84	0.89	0.92	1.00
male	harm	W2	CCW, A vs B1 (reference)	V3_random	21.76	21.28	21.28	0.48	0.67	0.00	6.65	0.86	0.87	0.97
male	harm	W2	CCW, A vs B1 (reference)	V4_within	21.04	21.28	21.28	-0.25	0.75	0.00	7.54	0.83	0.92	0.90
male	harm	W3	Naive ‘ever early PVI’	V1_ignore	25.39	22.52	14.23	2.86	0.85	8.30	2.24	0.90	0.67	1.00
male	harm	W3	Naive ‘ever early PVI’	V2_cluster	25.39	22.52	14.23	2.86	0.85	8.30	2.24	0.94	0.70	1.00
male	harm	W3	Naive ‘ever early PVI’	V3_random	20.57	22.52	14.23	-1.96	0.77	8.30	2.93	0.99	0.87	1.00
male	harm	W3	Naive ‘ever early PVI’	V4_within	17.19	22.52	14.23	-5.34	0.84	8.30	3.22	0.99	0.58	1.00
male	harm	W3	Landmark at 6 months	V1_ignore	26.39	16.51	14.23	9.88	0.72	2.28	4.38	1.06	0.40	1.00
male	harm	W3	Landmark at 6 months	V2_cluster	26.39	16.51	14.23	9.88	0.72	2.28	4.38	1.06	0.38	1.00
male	harm	W3	Landmark at 6 months	V3_random	20.39	16.51	14.23	3.88	0.59	2.28	5.75	0.88	0.83	0.98
male	harm	W3	Landmark at 6 months	V4_within	18.26	16.51	14.23	1.75	0.64	2.28	6.87	0.85	0.90	0.88
male	harm	W3	Sequential trials, ITT	V1_ignore	24.40	15.28	14.23	9.12	0.22	1.05	2.19	0.88	0.00	1.00
male	harm	W3	Sequential trials, ITT	V2_cluster	24.40	15.28	14.23	9.12	0.22	1.05	2.19	0.93	0.01	1.00
male	harm	W3	Sequential trials, ITT	V3_random	18.25	15.28	14.23	2.97	0.26	1.05	2.56	0.94	0.72	1.00
male	harm	W3	Sequential trials, ITT	V4_within	16.65	15.28	14.23	1.37	0.29	1.05	2.92	0.90	0.91	1.00
male	harm	W3	CCW, A vs B2	V1_ignore	22.67	14.65	14.23	8.02	0.45	0.43	4.54	0.99	0.57	1.00
male	harm	W3	CCW, A vs B2	V2_cluster	22.67	14.65	14.23	8.02	0.45	0.43	4.54	1.00	0.59	1.00
male	harm	W3	CCW, A vs B2	V3_random	17.12	14.65	14.23	2.47	0.53	0.43	5.26	1.00	0.92	0.93
male	harm	W3	CCW, A vs B2	V4_within	16.27	14.65	14.23	1.62	0.60	0.43	5.98	0.96	0.92	0.86
male	harm	W3	CCW, A vs B1 (reference)	V1_ignore	22.34	14.23	14.23	8.12	0.45	0.00	4.53	0.99	0.57	1.00
male	harm	W3	CCW, A vs B1 (reference)	V2_cluster	22.34	14.23	14.23	8.12	0.45	0.00	4.53	1.00	0.59	1.00
male	harm	W3	CCW, A vs B1 (reference)	V3_random	16.72	14.23	14.23	2.50	0.53	0.00	5.27	1.00	0.92	0.93
male	harm	W3	CCW, A vs B1 (reference)	V4_within	15.51	14.23	14.23	1.29	0.60	0.00	6.00	0.96	0.90	0.83
male	harm	W4	Naive ‘ever early PVI’	V1_ignore	21.37	21.46	18.95	-0.09	0.09	2.51	1.92	1.01	0.94	1.00
male	harm	W4	Naive ‘ever early PVI’	V2_cluster	21.37	21.46	18.95	-0.09	0.09	2.51	1.92	1.00	0.93	1.00
male	harm	W4	Naive ‘ever early PVI’	V3_random	21.46	21.46	18.95	-0.00	0.08	2.51	2.05	0.97	0.92	1.00
male	harm	W4	Naive ‘ever early PVI’	V4_within	20.37	21.46	18.95	-1.09	0.16	2.51	2.73	0.91	0.92	1.00
male	harm	W4	Landmark at 6 months	V1_ignore	22.73	22.70	18.95	0.03	0.26	3.75	4.69	1.01	0.92	0.98
male	harm	W4	Landmark at 6 months	V2_cluster	22.73	22.70	18.95	0.03	0.26	3.75	4.69	1.01	0.92	0.98
male	harm	W4	Landmark at 6 months	V3_random	22.83	22.70	18.95	0.13	0.22	3.75	4.92	0.98	0.92	0.99
male	harm	W4	Landmark at 6 months	V4_within	22.49	22.70	18.95	-0.22	0.41	3.75	6.65	0.93	0.91	0.98
male	harm	W4	Sequential trials, ITT	V1_ignore	20.43	20.53	18.95	-0.10	0.19	1.58	1.87	0.99	0.96	1.00
male	harm	W4	Sequential trials, ITT	V2_cluster	20.43	20.53	18.95	-0.10	0.19	1.58	1.87	0.98	0.96	1.00
male	harm	W4	Sequential trials, ITT	V3_random	20.36	20.53	18.95	-0.17	0.20	1.58	2.00	0.94	0.96	1.00
male	harm	W4	Sequential trials, ITT	V4_within	19.72	20.53	18.95	-0.82	0.26	1.58	2.60	0.86	0.89	1.00
male	harm	W4	CCW, A vs B2	V1_ignore	20.89	20.93	18.95	-0.05	0.42	1.98	4.25	1.01	0.93	1.00
male	harm	W4	CCW, A vs B2	V2_cluster	20.89	20.93	18.95	-0.05	0.42	1.98	4.25	1.00	0.93	1.00
male	harm	W4	CCW, A vs B2	V3_random	20.96	20.93	18.95	0.03	0.42	1.98	4.25	1.02	0.94	1.00
male	harm	W4	CCW, A vs B2	V4_within	20.84	20.93	18.95	-0.09	0.50	1.98	4.99	1.00	0.95	1.00
male	harm	W4	CCW, A vs B1 (reference)	V1_ignore	19.00	18.95	18.95	0.05	0.43	0.00	4.27	1.00	0.94	0.99
male	harm	W4	CCW, A vs B1 (reference)	V2_cluster	19.00	18.95	18.95	0.05	0.43	0.00	4.27	1.00	0.93	0.99
male	harm	W4	CCW, A vs B1 (reference)	V3_random	18.99	18.95	18.95	0.04	0.43	0.00	4.26	1.02	0.94	1.00
male	harm	W4	CCW, A vs B1 (reference)	V4_within	18.71	18.95	18.95	-0.24	0.50	0.00	4.99	1.00	0.94	0.99
male	harm	W5	Naive ‘ever early PVI’	V1_ignore	30.43	23.61	20.68	6.83	0.16	2.93	1.40	1.01	0.00	1.00
male	harm	W5	Naive ‘ever early PVI’	V2_cluster	30.43	23.61	20.68	6.83	0.16	2.93	1.40	1.01	0.00	1.00
male	harm	W5	Naive ‘ever early PVI’	V3_random	30.52	23.61	20.68	6.92	0.15	2.93	1.39	1.04	0.00	1.00
male	harm	W5	Naive ‘ever early PVI’	V4_within	30.35	23.61	20.68	6.74	0.16	2.93	1.57	1.10	0.02	1.00
male	harm	W5	Landmark at 6 months	V1_ignore	28.38	24.51	20.68	3.88	0.46	3.83	1.52	1.00	0.25	1.00
male	harm	W5	Landmark at 6 months	V2_cluster	28.38	24.51	20.68	3.88	0.46	3.83	1.52	1.00	0.27	1.00
male	harm	W5	Landmark at 6 months	V3_random	28.44	24.51	20.68	3.93	0.46	3.83	1.51	1.03	0.23	1.00
male	harm	W5	Landmark at 6 months	V4_within	28.38	24.51	20.68	3.87	0.46	3.83	1.74	1.07	0.46	1.00
male	harm	W5	Sequential trials, ITT	V1_ignore	28.40	22.23	20.68	6.18	0.15	1.55	1.49	1.00	0.00	1.00
male	harm	W5	Sequential trials, ITT	V2_cluster	28.40	22.23	20.68	6.18	0.15	1.55	1.49	1.00	0.00	1.00
male	harm	W5	Sequential trials, ITT	V3_random	28.42	22.23	20.68	6.19	0.15	1.55	1.49	1.02	0.00	1.00
male	harm	W5	Sequential trials, ITT	V4_within	28.30	22.23	20.68	6.07	0.17	1.55	1.70	1.05	0.09	1.00
male	harm	W5	CCW, A vs B2	V1_ignore	27.11	20.98	20.68	6.14	0.30	0.30	3.00	1.12	0.55	1.00
male	harm	W5	CCW, A vs B2	V2_cluster	27.11	20.98	20.68	6.14	0.30	0.30	3.00	1.13	0.55	1.00
male	harm	W5	CCW, A vs B2	V3_random	27.26	20.98	20.68	6.28	0.30	0.30	3.00	1.14	0.56	1.00
male	harm	W5	CCW, A vs B2	V4_within	27.54	20.98	20.68	6.57	0.38	0.30	3.82	1.05	0.58	1.00
male	harm	W5	CCW, A vs B1 (reference)	V1_ignore	26.83	20.68	20.68	6.15	0.30	0.00	3.00	1.12	0.56	1.00
male	harm	W5	CCW, A vs B1 (reference)	V2_cluster	26.83	20.68	20.68	6.15	0.30	0.00	3.00	1.13	0.54	1.00
male	harm	W5	CCW, A vs B1 (reference)	V3_random	26.98	20.68	20.68	6.30	0.30	0.00	3.01	1.14	0.56	1.00
male	harm	W5	CCW, A vs B1 (reference)	V4_within	27.23	20.68	20.68	6.56	0.38	0.00	3.82	1.05	0.58	1.00
male	harm	WR	Naive ‘ever early PVI’	V1_ignore	33.93	23.60	14.48	10.32	0.89	9.12	2.19	0.73	0.00	1.00
male	harm	WR	Naive ‘ever early PVI’	V2_cluster	33.93	23.60	14.48	10.32	0.89	9.12	2.19	0.98	0.00	1.00
male	harm	WR	Naive ‘ever early PVI’	V3_random	28.96	23.60	14.48	5.35	0.87	9.12	2.34	0.93	0.34	1.00
male	harm	WR	Naive ‘ever early PVI’	V4_within	26.99	23.60	14.48	3.39	0.89	9.12	2.54	0.96	0.72	1.00
male	harm	WR	Landmark at 6 months	V1_ignore	32.12	25.25	14.48	6.87	1.13	10.76	2.34	0.73	0.07	1.00
male	harm	WR	Landmark at 6 months	V2_cluster	32.12	25.25	14.48	6.87	1.13	10.76	2.34	0.96	0.11	1.00
male	harm	WR	Landmark at 6 months	V3_random	26.34	25.25	14.48	1.09	1.15	10.76	2.35	0.97	0.93	1.00
male	harm	WR	Landmark at 6 months	V4_within	24.97	25.25	14.48	-0.28	1.17	10.76	2.65	0.99	0.96	1.00
male	harm	WR	Sequential trials, ITT	V1_ignore	32.28	15.51	14.48	16.77	0.22	1.03	2.23	0.74	0.00	1.00
male	harm	WR	Sequential trials, ITT	V2_cluster	32.28	15.51	14.48	16.77	0.22	1.03	2.23	0.99	0.00	1.00
male	harm	WR	Sequential trials, ITT	V3_random	26.26	15.51	14.48	10.75	0.23	1.03	2.31	0.95	0.00	1.00
male	harm	WR	Sequential trials, ITT	V4_within	24.74	15.51	14.48	9.23	0.25	1.03	2.54	0.95	0.03	1.00
male	harm	WR	CCW, A vs B2	V1_ignore	29.38	14.99	14.48	14.40	0.47	0.50	4.66	0.84	0.07	1.00
male	harm	WR	CCW, A vs B2	V2_cluster	29.38	14.99	14.48	14.40	0.47	0.50	4.66	0.88	0.08	1.00
male	harm	WR	CCW, A vs B2	V3_random	24.96	14.99	14.48	9.98	0.53	0.50	5.34	0.88	0.49	1.00
male	harm	WR	CCW, A vs B2	V4_within	24.54	14.99	14.48	9.55	0.58	0.50	5.82	0.90	0.59	1.00
male	harm	WR	CCW, A vs B1 (reference)	V1_ignore	28.98	14.48	14.48	14.49	0.46	0.00	4.64	0.84	0.07	1.00
male	harm	WR	CCW, A vs B1 (reference)	V2_cluster	28.98	14.48	14.48	14.49	0.46	0.00	4.64	0.88	0.08	1.00
male	harm	WR	CCW, A vs B1 (reference)	V3_random	24.46	14.48	14.48	9.98	0.53	0.00	5.35	0.88	0.48	1.00
male	harm	WR	CCW, A vs B1 (reference)	V4_within	23.60	14.48	14.48	9.12	0.58	0.00	5.84	0.90	0.60	1.00
male	null	W0	Naive ‘ever early PVI’	V1_ignore	16.02	16.18	14.23	-0.16	0.09	1.95	1.70	1.06	0.93	1.00
male	null	W0	Naive ‘ever early PVI’	V2_cluster	16.02	16.18	14.23	-0.16	0.09	1.95	1.70	1.05	0.93	1.00
male	null	W0	Naive ‘ever early PVI’	V3_random	16.13	16.18	14.23	-0.05	0.08	1.95	1.73	1.06	0.96	1.00
male	null	W0	Naive ‘ever early PVI’	V4_within	15.50	16.18	14.23	-0.68	0.17	1.95	2.28	1.01	0.94	1.00
male	null	W0	Landmark at 6 months	V1_ignore	14.79	14.68	14.23	0.11	0.09	0.45	1.78	1.00	0.95	1.00
male	null	W0	Landmark at 6 months	V2_cluster	14.79	14.68	14.23	0.11	0.09	0.45	1.78	1.00	0.94	1.00
male	null	W0	Landmark at 6 months	V3_random	14.86	14.68	14.23	0.19	0.08	0.45	1.82	0.99	0.93	1.00
male	null	W0	Landmark at 6 months	V4_within	14.59	14.68	14.23	-0.09	0.15	0.45	2.38	0.96	0.93	1.00
male	null	W0	Sequential trials, ITT	V1_ignore	15.07	15.06	14.23	0.01	0.17	0.84	1.69	1.01	0.96	1.00
male	null	W0	Sequential trials, ITT	V2_cluster	15.07	15.06	14.23	0.01	0.17	0.84	1.69	1.00	0.96	1.00
male	null	W0	Sequential trials, ITT	V3_random	15.06	15.06	14.23	-0.00	0.17	0.84	1.75	0.99	0.94	1.00
male	null	W0	Sequential trials, ITT	V4_within	14.84	15.06	14.23	-0.22	0.22	0.84	2.15	0.96	0.93	1.00
male	null	W0	CCW, A vs B2	V1_ignore	14.32	14.47	14.23	-0.15	0.40	0.24	3.98	0.95	0.93	0.97
male	null	W0	CCW, A vs B2	V2_cluster	14.32	14.47	14.23	-0.15	0.40	0.24	3.98	0.95	0.93	0.98
male	null	W0	CCW, A vs B2	V3_random	14.49	14.47	14.23	0.02	0.40	0.24	3.98	0.97	0.94	0.98
male	null	W0	CCW, A vs B2	V4_within	14.70	14.47	14.23	0.24	0.46	0.24	4.57	1.01	0.93	0.95
male	null	W0	CCW, A vs B1 (reference)	V1_ignore	14.09	14.23	14.23	-0.14	0.40	0.00	3.98	0.95	0.93	0.97
male	null	W0	CCW, A vs B1 (reference)	V2_cluster	14.09	14.23	14.23	-0.14	0.40	0.00	3.98	0.95	0.93	0.97
male	null	W0	CCW, A vs B1 (reference)	V3_random	14.26	14.23	14.23	0.03	0.40	0.00	3.98	0.97	0.94	0.97
male	null	W0	CCW, A vs B1 (reference)	V4_within	14.45	14.23	14.23	0.22	0.46	0.00	4.57	1.01	0.93	0.95
male	null	W1	Naive ‘ever early PVI’	V1_ignore	16.45	15.62	13.86	0.83	0.11	1.76	2.09	0.88	0.92	1.00
male	null	W1	Naive ‘ever early PVI’	V2_cluster	16.45	15.62	13.86	0.83	0.11	1.76	2.09	0.90	0.93	1.00
male	null	W1	Naive ‘ever early PVI’	V3_random	16.28	15.62	13.86	0.66	0.09	1.76	2.15	0.89	0.94	1.00
male	null	W1	Naive ‘ever early PVI’	V4_within	15.25	15.62	13.86	-0.37	0.16	1.76	2.48	0.95	0.92	1.00
male	null	W1	Landmark at 6 months	V1_ignore	15.04	13.92	13.86	1.12	0.09	0.05	1.96	0.92	0.90	1.00
male	null	W1	Landmark at 6 months	V2_cluster	15.04	13.92	13.86	1.12	0.09	0.05	1.96	0.94	0.92	1.00
male	null	W1	Landmark at 6 months	V3_random	14.80	13.92	13.86	0.89	0.08	0.05	1.96	0.94	0.93	1.00
male	null	W1	Landmark at 6 months	V4_within	14.10	13.92	13.86	0.18	0.15	0.05	2.39	0.95	0.94	1.00
male	null	W1	Sequential trials, ITT	V1_ignore	15.43	14.62	13.86	0.80	0.19	0.76	1.92	0.90	0.91	1.00
male	null	W1	Sequential trials, ITT	V2_cluster	15.43	14.62	13.86	0.80	0.19	0.76	1.92	0.92	0.92	1.00
male	null	W1	Sequential trials, ITT	V3_random	15.10	14.62	13.86	0.47	0.20	0.76	1.96	0.91	0.95	1.00
male	null	W1	Sequential trials, ITT	V4_within	14.47	14.62	13.86	-0.15	0.23	0.76	2.31	0.92	0.91	1.00
male	null	W1	CCW, A vs B2	V1_ignore	14.86	14.12	13.86	0.74	0.41	0.25	4.12	0.96	0.94	0.99
male	null	W1	CCW, A vs B2	V2_cluster	14.86	14.12	13.86	0.74	0.41	0.25	4.12	0.97	0.94	0.99
male	null	W1	CCW, A vs B2	V3_random	14.51	14.12	13.86	0.39	0.41	0.25	4.13	0.97	0.93	0.99
male	null	W1	CCW, A vs B2	V4_within	14.43	14.12	13.86	0.31	0.48	0.25	4.84	0.96	0.94	0.94
male	null	W1	CCW, A vs B1 (reference)	V1_ignore	14.61	13.86	13.86	0.75	0.41	0.00	4.12	0.96	0.94	0.99
male	null	W1	CCW, A vs B1 (reference)	V2_cluster	14.61	13.86	13.86	0.75	0.41	0.00	4.12	0.97	0.94	0.99
male	null	W1	CCW, A vs B1 (reference)	V3_random	14.26	13.86	13.86	0.40	0.41	0.00	4.13	0.97	0.92	0.99
male	null	W1	CCW, A vs B1 (reference)	V4_within	14.15	13.86	13.86	0.29	0.48	0.00	4.84	0.96	0.94	0.93
male	null	W1_rho0	Naive ‘ever early PVI’	V1_ignore	16.29	16.39	14.77	-0.10	0.09	1.62	1.74	1.05	0.96	1.00
male	null	W1_rho0	Naive ‘ever early PVI’	V2_cluster	16.29	16.39	14.77	-0.10	0.09	1.62	1.74	1.07	0.97	1.00
male	null	W1_rho0	Naive ‘ever early PVI’	V3_random	16.44	16.39	14.77	0.05	0.08	1.62	1.81	1.05	0.97	1.00
male	null	W1_rho0	Naive ‘ever early PVI’	V4_within	15.88	16.39	14.77	-0.51	0.14	1.62	2.17	1.07	0.95	1.00
male	null	W1_rho0	Landmark at 6 months	V1_ignore	15.01	14.92	14.77	0.09	0.10	0.15	1.64	1.10	0.98	1.00
male	null	W1_rho0	Landmark at 6 months	V2_cluster	15.01	14.92	14.77	0.09	0.10	0.15	1.64	1.12	0.98	1.00
male	null	W1_rho0	Landmark at 6 months	V3_random	15.11	14.92	14.77	0.19	0.08	0.15	1.69	1.11	0.98	1.00
male	null	W1_rho0	Landmark at 6 months	V4_within	14.90	14.92	14.77	-0.03	0.13	0.15	2.01	1.15	0.98	1.00
male	null	W1_rho0	Sequential trials, ITT	V1_ignore	15.36	15.62	14.77	-0.26	0.17	0.84	1.65	1.05	0.98	1.00
male	null	W1_rho0	Sequential trials, ITT	V2_cluster	15.36	15.62	14.77	-0.26	0.17	0.84	1.65	1.07	0.98	1.00
male	null	W1_rho0	Sequential trials, ITT	V3_random	15.35	15.62	14.77	-0.27	0.17	0.84	1.71	1.05	0.97	1.00
male	null	W1_rho0	Sequential trials, ITT	V4_within	15.16	15.62	14.77	-0.45	0.20	0.84	2.00	1.08	0.95	1.00
male	null	W1_rho0	CCW, A vs B2	V1_ignore	14.99	15.02	14.77	-0.03	0.33	0.25	3.25	1.20	0.98	1.00
male	null	W1_rho0	CCW, A vs B2	V2_cluster	14.99	15.02	14.77	-0.03	0.33	0.25	3.25	1.21	0.99	1.00
male	null	W1_rho0	CCW, A vs B2	V3_random	14.95	15.02	14.77	-0.07	0.34	0.25	3.41	1.16	0.97	1.00
male	null	W1_rho0	CCW, A vs B2	V4_within	14.83	15.02	14.77	-0.19	0.40	0.25	4.03	1.14	0.96	0.96
male	null	W1_rho0	CCW, A vs B1 (reference)	V1_ignore	14.75	14.77	14.77	-0.02	0.33	0.00	3.25	1.20	0.98	1.00
male	null	W1_rho0	CCW, A vs B1 (reference)	V2_cluster	14.75	14.77	14.77	-0.02	0.33	0.00	3.25	1.21	0.98	1.00
male	null	W1_rho0	CCW, A vs B1 (reference)	V3_random	14.71	14.77	14.77	-0.06	0.34	0.00	3.41	1.16	0.97	0.98
male	null	W1_rho0	CCW, A vs B1 (reference)	V4_within	14.57	14.77	14.77	-0.20	0.40	0.00	4.03	1.14	0.96	0.96
male	null	W2	Naive ‘ever early PVI’	V1_ignore	17.43	26.14	14.83	-8.72	0.99	11.32	1.84	1.02	0.02	1.00
male	null	W2	Naive ‘ever early PVI’	V2_cluster	17.43	26.14	14.83	-8.72	0.99	11.32	1.84	1.03	0.01	1.00
male	null	W2	Naive ‘ever early PVI’	V3_random	18.38	26.14	14.83	-7.76	0.97	11.32	2.92	1.06	0.26	1.00
male	null	W2	Naive ‘ever early PVI’	V4_within	15.80	26.14	14.83	-10.34	1.06	11.32	3.66	0.97	0.16	1.00
male	null	W2	Landmark at 6 months	V1_ignore	16.05	16.06	14.83	-0.00	0.54	1.23	1.80	1.02	0.95	1.00
male	null	W2	Landmark at 6 months	V2_cluster	16.05	16.06	14.83	-0.00	0.54	1.23	1.80	1.03	0.95	1.00
male	null	W2	Landmark at 6 months	V3_random	15.72	16.06	14.83	-0.34	0.50	1.23	2.91	0.99	0.95	1.00
male	null	W2	Landmark at 6 months	V4_within	14.82	16.06	14.83	-1.24	0.53	1.23	3.83	0.93	0.87	0.99
male	null	W2	Sequential trials, ITT	V1_ignore	16.34	15.74	14.83	0.60	0.17	0.91	1.73	1.02	0.94	1.00
male	null	W2	Sequential trials, ITT	V2_cluster	16.34	15.74	14.83	0.60	0.17	0.91	1.73	1.02	0.95	1.00
male	null	W2	Sequential trials, ITT	V3_random	15.84	15.74	14.83	0.10	0.25	0.91	2.54	0.96	0.96	1.00
male	null	W2	Sequential trials, ITT	V4_within	15.04	15.74	14.83	-0.70	0.30	0.91	2.97	0.90	0.91	1.00
male	null	W2	CCW, A vs B2	V1_ignore	15.65	15.14	14.83	0.51	0.42	0.31	4.19	0.99	0.93	1.00
male	null	W2	CCW, A vs B2	V2_cluster	15.65	15.14	14.83	0.51	0.42	0.31	4.19	0.98	0.93	1.00
male	null	W2	CCW, A vs B2	V3_random	15.80	15.14	14.83	0.66	0.64	0.31	6.38	0.85	0.96	0.91
male	null	W2	CCW, A vs B2	V4_within	15.42	15.14	14.83	0.28	0.75	0.31	7.49	0.78	0.94	0.79
male	null	W2	CCW, A vs B1 (reference)	V1_ignore	15.39	14.83	14.83	0.57	0.42	0.00	4.19	0.99	0.93	1.00
male	null	W2	CCW, A vs B1 (reference)	V2_cluster	15.39	14.83	14.83	0.57	0.42	0.00	4.19	0.98	0.93	1.00
male	null	W2	CCW, A vs B1 (reference)	V3_random	15.51	14.83	14.83	0.68	0.64	0.00	6.38	0.85	0.96	0.91
male	null	W2	CCW, A vs B1 (reference)	V4_within	14.89	14.83	14.83	0.06	0.75	0.00	7.49	0.78	0.95	0.76
male	null	W3	Naive ‘ever early PVI’	V1_ignore	18.46	17.59	7.97	0.88	0.71	9.62	2.03	0.93	0.91	1.00
male	null	W3	Naive ‘ever early PVI’	V2_cluster	18.46	17.59	7.97	0.88	0.71	9.62	2.03	1.01	0.94	1.00
male	null	W3	Naive ‘ever early PVI’	V3_random	14.04	17.59	7.97	-3.55	0.67	9.62	2.84	0.95	0.70	0.99
male	null	W3	Naive ‘ever early PVI’	V4_within	10.77	17.59	7.97	-6.82	0.73	9.62	2.97	0.97	0.32	0.98
male	null	W3	Landmark at 6 months	V1_ignore	16.96	8.32	7.97	8.65	0.43	0.34	1.99	0.94	0.00	1.00
male	null	W3	Landmark at 6 months	V2_cluster	16.96	8.32	7.97	8.65	0.43	0.34	1.99	1.03	0.00	1.00
male	null	W3	Landmark at 6 months	V3_random	11.32	8.32	7.97	3.01	0.35	0.34	2.41	0.99	0.77	0.99
male	null	W3	Landmark at 6 months	V4_within	9.67	8.32	7.97	1.35	0.37	0.34	2.91	0.96	0.93	0.93
male	null	W3	Sequential trials, ITT	V1_ignore	17.39	8.27	7.97	9.12	0.20	0.29	2.01	0.89	0.00	1.00
male	null	W3	Sequential trials, ITT	V2_cluster	17.39	8.27	7.97	9.12	0.20	0.29	2.01	0.98	0.00	1.00
male	null	W3	Sequential trials, ITT	V3_random	11.54	8.27	7.97	3.28	0.23	0.29	2.32	0.94	0.73	1.00
male	null	W3	Sequential trials, ITT	V4_within	10.24	8.27	7.97	1.97	0.26	0.29	2.59	0.92	0.83	1.00
male	null	W3	CCW, A vs B2	V1_ignore	14.62	8.33	7.97	6.29	0.41	0.36	4.06	0.99	0.70	0.98
male	null	W3	CCW, A vs B2	V2_cluster	14.62	8.33	7.97	6.29	0.41	0.36	4.06	1.01	0.70	0.97
male	null	W3	CCW, A vs B2	V3_random	10.29	8.33	7.97	1.96	0.47	0.36	4.70	1.00	0.94	0.59
male	null	W3	CCW, A vs B2	V4_within	9.53	8.33	7.97	1.20	0.50	0.36	4.96	1.03	0.93	0.49
male	null	W3	CCW, A vs B1 (reference)	V1_ignore	14.34	7.97	7.97	6.37	0.41	0.00	4.06	0.99	0.68	0.98
male	null	W3	CCW, A vs B1 (reference)	V2_cluster	14.34	7.97	7.97	6.37	0.41	0.00	4.06	1.01	0.66	0.97
male	null	W3	CCW, A vs B1 (reference)	V3_random	9.95	7.97	7.97	1.98	0.47	0.00	4.69	1.00	0.94	0.59
male	null	W3	CCW, A vs B1 (reference)	V4_within	8.90	7.97	7.97	0.92	0.49	0.00	4.94	1.03	0.93	0.40
male	null	W4	Naive ‘ever early PVI’	V1_ignore	14.52	14.94	12.85	-0.41	0.10	2.08	1.72	1.06	0.97	1.00
male	null	W4	Naive ‘ever early PVI’	V2_cluster	14.52	14.94	12.85	-0.41	0.10	2.08	1.72	1.06	0.96	1.00
male	null	W4	Naive ‘ever early PVI’	V3_random	14.69	14.94	12.85	-0.25	0.10	2.08	1.79	1.05	0.96	1.00
male	null	W4	Naive ‘ever early PVI’	V4_within	14.02	14.94	12.85	-0.92	0.15	2.08	2.27	1.06	0.90	1.00
male	null	W4	Landmark at 6 months	V1_ignore	13.33	13.36	12.85	-0.03	0.09	0.51	1.62	1.12	0.99	1.00
male	null	W4	Landmark at 6 months	V2_cluster	13.33	13.36	12.85	-0.03	0.09	0.51	1.62	1.11	0.99	1.00
male	null	W4	Landmark at 6 months	V3_random	13.45	13.36	12.85	0.09	0.08	0.51	1.67	1.11	1.00	1.00
male	null	W4	Landmark at 6 months	V4_within	13.06	13.36	12.85	-0.30	0.13	0.51	2.18	1.10	0.99	1.00
male	null	W4	Sequential trials, ITT	V1_ignore	13.65	13.71	12.85	-0.07	0.16	0.86	1.61	1.07	0.97	1.00
male	null	W4	Sequential trials, ITT	V2_cluster	13.65	13.71	12.85	-0.07	0.16	0.86	1.61	1.07	0.97	1.00
male	null	W4	Sequential trials, ITT	V3_random	13.69	13.71	12.85	-0.02	0.16	0.86	1.64	1.08	0.98	1.00
male	null	W4	Sequential trials, ITT	V4_within	13.39	13.71	12.85	-0.32	0.20	0.86	2.00	1.07	0.98	1.00
male	null	W4	CCW, A vs B2	V1_ignore	15.25	14.41	12.85	0.84	0.39	1.56	3.95	1.02	0.95	1.00
male	null	W4	CCW, A vs B2	V2_cluster	15.25	14.41	12.85	0.84	0.39	1.56	3.95	1.01	0.95	0.99
male	null	W4	CCW, A vs B2	V3_random	15.29	14.41	12.85	0.88	0.39	1.56	3.93	1.03	0.94	1.00
male	null	W4	CCW, A vs B2	V4_within	14.79	14.41	12.85	0.38	0.44	1.56	4.45	1.07	0.98	0.93
male	null	W4	CCW, A vs B1 (reference)	V1_ignore	13.76	12.85	12.85	0.91	0.39	0.00	3.94	1.02	0.95	0.98
male	null	W4	CCW, A vs B1 (reference)	V2_cluster	13.76	12.85	12.85	0.91	0.39	0.00	3.94	1.01	0.95	0.99
male	null	W4	CCW, A vs B1 (reference)	V3_random	13.73	12.85	12.85	0.88	0.39	0.00	3.93	1.03	0.94	0.99
male	null	W4	CCW, A vs B1 (reference)	V4_within	13.19	12.85	12.85	0.34	0.44	0.00	4.37	1.08	0.98	0.87
male	null	W5	Naive ‘ever early PVI’	V1_ignore	21.97	16.04	14.23	5.94	0.16	1.81	1.30	1.05	0.01	1.00
male	null	W5	Naive ‘ever early PVI’	V2_cluster	21.97	16.04	14.23	5.94	0.16	1.81	1.30	1.05	0.01	1.00
male	null	W5	Naive ‘ever early PVI’	V3_random	22.06	16.04	14.23	6.02	0.16	1.81	1.31	1.06	0.00	1.00
male	null	W5	Naive ‘ever early PVI’	V4_within	21.85	16.04	14.23	5.81	0.17	1.81	1.50	1.12	0.03	1.00
male	null	W5	Landmark at 6 months	V1_ignore	19.28	14.39	14.23	4.89	0.15	0.16	1.34	1.11	0.04	1.00
male	null	W5	Landmark at 6 months	V2_cluster	19.28	14.39	14.23	4.89	0.15	0.16	1.34	1.10	0.04	1.00
male	null	W5	Landmark at 6 months	V3_random	19.34	14.39	14.23	4.95	0.15	0.16	1.39	1.09	0.06	1.00
male	null	W5	Landmark at 6 months	V4_within	19.35	14.39	14.23	4.96	0.18	0.16	1.76	1.05	0.20	1.00
male	null	W5	Sequential trials, ITT	V1_ignore	20.21	15.06	14.23	5.14	0.13	0.84	1.30	1.08	0.03	1.00
male	null	W5	Sequential trials, ITT	V2_cluster	20.21	15.06	14.23	5.14	0.13	0.84	1.30	1.08	0.03	1.00
male	null	W5	Sequential trials, ITT	V3_random	20.24	15.06	14.23	5.17	0.13	0.84	1.30	1.11	0.03	1.00
male	null	W5	Sequential trials, ITT	V4_within	20.23	15.06	14.23	5.16	0.15	0.84	1.51	1.15	0.14	1.00
male	null	W5	CCW, A vs B2	V1_ignore	18.57	14.47	14.23	4.10	0.30	0.24	3.05	1.04	0.75	1.00
male	null	W5	CCW, A vs B2	V2_cluster	18.57	14.47	14.23	4.10	0.30	0.24	3.05	1.04	0.75	1.00
male	null	W5	CCW, A vs B2	V3_random	18.55	14.47	14.23	4.09	0.32	0.24	3.20	1.01	0.76	1.00
male	null	W5	CCW, A vs B2	V4_within	18.36	14.47	14.23	3.89	0.39	0.24	3.92	0.98	0.87	1.00
male	null	W5	CCW, A vs B1 (reference)	V1_ignore	18.34	14.23	14.23	4.11	0.31	0.00	3.05	1.04	0.75	1.00
male	null	W5	CCW, A vs B1 (reference)	V2_cluster	18.34	14.23	14.23	4.11	0.31	0.00	3.05	1.04	0.74	1.00
male	null	W5	CCW, A vs B1 (reference)	V3_random	18.32	14.23	14.23	4.10	0.32	0.00	3.21	1.00	0.76	1.00
male	null	W5	CCW, A vs B1 (reference)	V4_within	18.11	14.23	14.23	3.88	0.39	0.00	3.93	0.98	0.87	0.99
male	null	WR	Naive ‘ever early PVI’	V1_ignore	22.69	16.38	6.68	6.31	0.79	9.70	2.09	0.72	0.06	1.00
male	null	WR	Naive ‘ever early PVI’	V2_cluster	22.69	16.38	6.68	6.31	0.79	9.70	2.09	0.90	0.10	1.00
male	null	WR	Naive ‘ever early PVI’	V3_random	18.05	16.38	6.68	1.67	0.76	9.70	2.16	0.89	0.83	1.00
male	null	WR	Naive ‘ever early PVI’	V4_within	16.09	16.38	6.68	-0.29	0.79	9.70	2.39	0.88	0.89	1.00
male	null	WR	Landmark at 6 months	V1_ignore	20.28	7.01	6.68	13.27	0.47	0.33	2.24	0.72	0.00	1.00
male	null	WR	Landmark at 6 months	V2_cluster	20.28	7.01	6.68	13.27	0.47	0.33	2.24	0.89	0.00	1.00
male	null	WR	Landmark at 6 months	V3_random	14.69	7.01	6.68	7.68	0.41	0.33	2.28	0.86	0.05	1.00
male	null	WR	Landmark at 6 months	V4_within	13.64	7.01	6.68	6.63	0.42	0.33	2.62	0.86	0.18	1.00
male	null	WR	Sequential trials, ITT	V1_ignore	21.09	6.88	6.68	14.21	0.22	0.20	2.16	0.71	0.00	1.00
male	null	WR	Sequential trials, ITT	V2_cluster	21.09	6.88	6.68	14.21	0.22	0.20	2.16	0.89	0.00	1.00
male	null	WR	Sequential trials, ITT	V3_random	15.40	6.88	6.68	8.52	0.21	0.20	2.06	0.91	0.00	1.00
male	null	WR	Sequential trials, ITT	V4_within	14.30	6.88	6.68	7.42	0.23	0.20	2.30	0.89	0.09	1.00
male	null	WR	CCW, A vs B2	V1_ignore	18.57	7.05	6.68	11.52	0.39	0.37	3.90	0.92	0.10	1.00
male	null	WR	CCW, A vs B2	V2_cluster	18.57	7.05	6.68	11.52	0.39	0.37	3.90	0.96	0.11	1.00
male	null	WR	CCW, A vs B2	V3_random	14.24	7.05	6.68	7.19	0.47	0.37	4.68	0.86	0.63	0.97
male	null	WR	CCW, A vs B2	V4_within	13.73	7.05	6.68	6.68	0.51	0.37	5.08	0.85	0.72	0.92
male	null	WR	CCW, A vs B1 (reference)	V1_ignore	18.26	6.68	6.68	11.58	0.39	0.00	3.89	0.92	0.10	1.00
male	null	WR	CCW, A vs B1 (reference)	V2_cluster	18.26	6.68	6.68	11.58	0.39	0.00	3.89	0.96	0.11	1.00
male	null	WR	CCW, A vs B1 (reference)	V3_random	13.86	6.68	6.68	7.18	0.47	0.00	4.68	0.86	0.63	0.97
male	null	WR	CCW, A vs B1 (reference)	V4_within	13.01	6.68	6.68	6.33	0.51	0.00	5.07	0.85	0.74	0.90